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ABSTRACT 
Profiling of RNA in mouse mammary epithelial cells (MECs) isolated during 
pregnancy and lactation revealed that most differentially expressed microRNA 
(miRNA) precipitously declined at lactation. Since miR-150 exhibited the greatest 
decrease, its role in secretory activation was further investigated. Concurrent 
investigation of miR-150 in the context of breast cancer (BC) revealed that miR-150 
is dramatically lower in primary human BCs compared to adjacent normal epithelium 
by in situ hybridization, regardless of tumor estrogen receptor (ER) status. This 
dissertation aims to test the dual hypotheses that miR-150 plays a role in secretory 
activation and a tumor suppressive role in BC. 
To investigate the importance of the decline in miR-150 at lactation, miR-150 
was constitutively expressed in MECs by crossing ROSA26-lox-STOP-lox-miR-150 
mice with WAP-driven Cre recombinase mice. This resulted in a dramatic decrease 
in survival of both biological and foster pups nursed by bitransgenic dams compared 
to offspring nursed by controls. Protein products of predicted miR-150 targets FASN, 
OLAH, ACACA, and STAT5B were significantly suppressed in MECs of bitransgenic 
mice compared to control mice at lactation, and lipid profiling of MECs from 




The tumor suppressive role of miR-150 in BC was investigated by restoring 
miR-150 to BC cell lines representing both ER+ and ER- BC subtypes. Proliferation 
assays revealed significant growth suppression upon restoration of miR-150 to cell 
lines of both subtypes. Two validated miR-150 targets were suppressed by miR-150 
at the protein level, Myb in ER+ BC and ZEB-1 in ER- BC. Expression profiling 
following miR-150 restoration to representative ER- and ER+ BC cell lines revealed 
novel, subtype specific, targets. Pathways enriched by miR-150 restoration in the 
ER- BC cell line involve reversal of epithelial to mesenchymal transition, while 
restoration of miR-150 to the ER+ BC cell line downregulated the fatty acid synthesis 
pathway among others. Because the ER+ BC cells are more differentiated, they are 
likely to share similar targets to normal MECs as presented herein. Since miR-150 
expression is lost in both BC subtypes, restoration of this miRNA could be a widely 
effective therapy. 
The form and content of this abstract are approved. I recommend its publication. 
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Mammary Gland Development 
A defining characteristic of mammals is the ability of females to nurse their 
young with milk secreted from mammary glands. For some mammals, mammary 
glands are located in a protruding organ, such as the breasts in humans and other 
primates. Development of this tissue from a rudimentary ductal tree structure at birth 
to a fully mature lactating gland can be divided into two stages of controlled 
proliferative expansion followed by lactation and involution (Fig. 1.1). These stages 
of mammary gland development are regulated in part by specific hormones and local 
environmental signals.  
The majority of expansion and differentiation of the mammary gland 
epithelium occurs postnatal, beginning during puberty. With the onset of puberty, 
there is rapid proliferation of mammary epithelial cells (MECs) as the rudimentary 
ducts elongate and branch out into the surrounding stroma of the mammary gland. 
This branching morphogenesis is triggered by an increase in the circulating ovarian 
hormone estrogen [1], which binds to estrogen receptor (ER)α within a subset of 
MECs [2]. Growth hormone and insulin-like growth factor-1 also influence ductal 
morphogenesis [3, 4]. At the end of this stage of development, there exists an 
extensive ductal network. 
The second major proliferative phase of mammary gland development occurs 
post pubertal. This begins with an increase in secondary and tertiary branching of 




Figure 1.1. Postnatal mouse mammary gland development. From Macias and 
Hinck, Mammary gland development. Wiley Interdisciplinary Reviews: 




progesterone binding to progesterone receptor (PR) in MECs [6]. Development 
advances even further during early to mid-pregnancy when specialized luminal 
epithelial cells located at the terminal ends of ducts rapidly proliferate to form alveoli, 
structures that synthesize and secrete milk. Proliferation of the alveoli, or 
alveologenesis, is driven by progesterone, but only occurs upon activation of the 
prolactin receptor by the pituitary hormone prolactin [7, 8]. Once proliferation ceases, 
secretory differentiation can ensue, and MECs prepare for lactation during late 
pregnancy by synthesizing the transcripts necessary for various milk components 
such as milk proteins [9]. After pregnancy, the mammary gland reaches its full 
maturity and is ready to produce copious amounts of milk. 
Lactation is held in check until parturition when secretory activation is 
triggered. A plethora of genes from several categories must be translated in MECs 
at this stage to achieve successful lactation and adequately nourish offspring. These 
critical lactation gene categories include genes involved in lipid synthesis [10], 
cholesterol synthesis [11], milk proteins [12], milk fat globule secretion [13], insulin 
signaling [14], tight junction proteins [15], and endocrine related genes [16]. It is 
important to note that while these genes are translated mainly during lactation, 
transcription of several genes begins during pregnancy (Fig. A.1) [9]. While it is 
known that a withdrawal of placenta sourced progesterone in the presence of 
prolactin and glucocorticoid initiates lactation, and suckling by offspring maintains 
the lactation state through prolactin and oxytocin signaling, the mechanisms involved 
are not fully understood [17]. Part of the work compiled for this dissertation aims to 
address one possible mechanism of translational control for such genes, allowing 
4 
 
them to be translated at the precise time necessary for the benefit of offspring 
survival. 
Once the need for milk ceases, involution sets in. Alveolar cells undergo 
apoptosis and tertiary branches regress. An influx of macrophages infiltrate the 
gland to phagocytose the apoptotic MECs and repopulate the gland with fibrous and 
adipocyte rich stroma [18], thus returning the gland close to its pre-pregnant state. 
Unlike other stages of mammary gland development, this is controlled by local 
signals within the mammary gland as opposed to circulating hormones [19, 20]. 
Development of the mammary gland is unique in that it continues well into 
adulthood. Each round of pregnancy initiates a new cycle of alveologenesis, 
lactation and involution. Some of the changes that occur during pregnancy also 
occur to some extent with the luteal phase of each ovarian cycle, when the ratio of 
circulating progesterone to estrogen is increased [7]. Consequently, the more 
ovulations a female goes through in her lifetime, the more cycles of proliferative 
growth and regression will occur in her mammary epithelium. 
Breast Cancer 
As with other hormone responsive tissues undergoing many rounds of 
proliferation, mammary epithelium has a high risk of developing malignancies. 
Mammary carcinoma, or breast cancer as it is called in humans, is the aberrant 
growth of MECs that make up either the ducts or the lobules at the terminal end of 
the ducts. If confined by the boundaries of the basement membrane, the growth is 
termed ductal carcinoma in situ, whereas if it has breached the basement membrane 
it is deemed invasive breast cancer. If the cancer reappears in distant sites, most 
5 
 
commonly the bone, liver, brain, lymph node and lung [21], the breast cancer has 
metastasized and is called metastatic breast cancer. This frequently occurs years 
after initial diagnosis, and is estimated to occur in 20-30% of all cases [22]. The 5-
year survival rate for breast cancer is only 89%, which is better than most cancer 
types. However, the median survival for those who had metastatic breast cancer, 
which can sometimes take 10 years to manifest, is a dismal 1.6 years if they didn’t 
have surgery and 2.3 years if they did have surgery [23]. Breast cancer is currently 
the leading cause of cancer death in women worldwide [24, 25]. As of January 2016, 
over 3.5 million American women were being treated for invasive breast cancer or 
were in remission, and an estimated quarter million more will be diagnosed in the 
United States by the end of the year [26]. While 75% of these survivors are 60 years 
of age or older, 7% (approximately a quarter million) are younger than 50 [26]. 
Despite all the advances made in early detection and treatment over the last 20 
years, breast cancer is still a major burden on today’s society, largely because of 
complications from metastatic disease and lack of effective treatments for 
metastasis. 
In the clinic, breast cancer is categorized by stage, grade, and receptor status 
as measured by immunohistochemistry (IHC) and fluorescence in situ hybridization 
(FISH). The stage designates tumor size and whether it is non-malignant (Stage 0), 
malignant (Stages I-III), or metastatic (Stage IV). Grade designates how abnormal 
the cells look histologically where the score can range from 1 (low grade, well 
differentiated) up to 3 (high grade, poorly differentiated). Receptor status is 
assessed for hormones ER and PR (by IHC) as well as amplification of human 
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epidermal growth factor receptor 2 (HER2) (by FISH). Seventy to 80% of all breast 
cancers are ER+, making it the most common breast cancer subtype [27]. Breast 
cancers that test positive for ER can benefit from anti-estrogen therapies, such as 
tamoxifen (a competitive inhibitor of estradiol) and aromatase inhibitors (which inhibit 
synthesis of estrogens from androgens), but patients continue to relapse due to an 
intrinsic or acquired resistance [28, 29]. Ten to 15% of breast cancers are HER2+ 
[30]. Breast cancers with an overexpression of HER2 benefit from monoclonal 
antibody therapies against HER2, such as trastuzumab, but the majority of patients 
with metastatic HER2 overexpressing breast cancer are also initially or eventually 
resistant [31]. Tumors that lack expression of ER, PR and amplification of HER2 are 
called triple negative breast cancer (TNBC). Since the main receptors that we have 
additional drugs for are missing in TNBC, it’s a subtype with high unmet treatment 
needs. Only traditional treatments (surgery, radiation, and chemotherapy) are 
effective for TNBC. TNBC has the worse prognosis and constitutes 15 to 20% of all 
breast cancers [32, 33]. What is particularly tragic about TNBC is that it is 
overrepresented in premenopausal as well as African-American women [33-38]. 
Therefore, while new therapies to treat the ER+ subtype would serve a greater 
percentage of patients, any targeted therapy that could be used to treat TNBC is 
highly sought after. Because ER+ breast cancer and TNBC represent the extreme 
ends of the spectrum, and together constitute the largest of the three clinical 
subtypes, the second part of this dissertation focuses on a novel regulator of gene 
expression in the context of these two breast cancer subtypes. 
A great deal of knowledge about breast cancer biology, including how to 
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potentially treat it and the risk factors involved, has come from research on 
mammary gland development. Both contexts share similar biological mechanisms 
because cancer cells frequently adapt by hijacking mechanisms relevant in 
developmental biology. Previous investigations into this relationship between 
development and cancer usually involve mechanisms relevant to embryonic 
development like epithelial to mesenchymal transition (EMT) [39, 40], which is a 
process that epithelial cells undergo to facilitate invasiveness and the ability to 
survive when detached from a basement membrane. Since the mammary gland 
continues to develop postnatally, there are also genes only expressed at appropriate 
times in the normal adult mammary gland. For example, Liu et. al. recently 
developed a mouse model for the tissue specific ablation of the transcription factor 
forkhead box protein A1 (Foxa1) [41]. They verified what Bernardo et al. showed ex 
vivo, that Foxa1 is essential for mammary duct formation [42]. Their model will prove 
useful for future research to determine mechanisms of FOXA1 regulation in human 
breast cancer where it promotes proliferation of ER+ breast cancer cells [43, 44]. 
Ultimately however, a better target to study would be something universal to multiple 
breast cancer subtypes that would limit the chance of drug resistance, of which the 
heterogenous composition of breast cancers have a long history acquiring [45, 46]. 
A master regulator of some universal breast cancer characteristic would be an ideal 
target. Discoveries of novel mechanisms of gene regulation in mammary gland 
development will provide additional insights in breast cancer research that could 




In the last decade, one of the largest subjects of research for the fields of 
development and cancer biology has been microRNAs (miRNAs). These are short 
(18-25 nucleotide) non-coding RNAs that regulate gene product expression primarily 
through post-transcriptional repression in a diverse array of life including plants, 
animals, and some viruses [47]. More than two thousand miRNAs are encoded in 
the human genome [48], which can be located intergenic or intragenic. These are 
speculated to regulate more than one third of all protein coding genes [49], but 
miRNAs can also target non-coding genes such as other miRNAs [50]. It is important 
to note that one miRNA can regulate hundreds of transcripts [51]. Additionally, each 
transcript can be targeted by an assortment of different miRNAs [51], perhaps as an 
evolutionary back-up mechanism to control translation of genes at different 
developmental time points or in different tissues. 
The biogenesis of miRNAs begins much like the transcription of any coding 
RNA, most commonly with RNA polymerase type II (RNA Pol II) [52, 53] (Fig. 1.2). 
Newly transcribed primary miRNA (pri-miRNA), contains a 5′ cap [52] and a poly-A 
tail [54] along with one or more precursor miRNAs (pre-miRNAs) folded up into 
hairpin structures that are about 70 nucleotides long. The canonical method by 
which pre-miRNAs are liberated from the pri-miRNA strand is by the RNase III 
enzyme drosha, which associates with the RNA binding protein DiGeorge syndrome 
critical region 8  (DGCR8) [55]. The nucleocytoplasmic shuttler exportin-5 exports 
the pre-miRNA out of the nucleus into the cytoplasm where it is further processed by 




Figure 1.2. miRNA biogenesis. Adapted from Winter et. al., Many roads to 



































duplex. This duplex dissociates to give mature single stranded miRNAs that 
originated from either the 5′ or 3′ end of the pre-miRNA. One strand is typically found 
in greater abundance than the other due to differences in stability, but both strands 
are fully functional. 
 miRNAs regulate gene product expression post-transcriptionally after 
incorporation into the miRNA-induced silencing complex (miRISC) [58]. Guided by 
the 6-8 nucleotide long seed sequence near the 5′ terminus of the miRNA [59], the 
miRISC can bind to complementary sites on target messenger RNAs (mRNAs) [60]. 
One or multiple copies of target sites are typically located in the 3′ untranslated 
region (UTR) of mRNAs [61], but target sites can also be located within the target 
gene or in the 5′ UTR [62]. For target sites with extensive pairing complementarity, 
the argonaute (Ago) proteins within the miRISC catalyze mRNA cleavage [63]. More 
commonly or in conjunction with mRNA cleavage, the miRISC association with 
target mRNA can lead to target destabilization and eventual degradation by mRNA 
deadenylation [64, 65]. Lastly, miRNA can also function by blocking initiation of 
translation [66], which leaves the transcript intact. Growing evidence indicates that 
miRNAs can be packaged into lipid vesicles and released into the extracellular 
space via exosomes to function in a paracrine manner [67]. Regardless of the 
method, the most common functional consequence of miRNA action is a decrease in 
the protein product of target genes. 
 Most targets of miRNAs can be predicted computationally [68], but they 
ultimately require biological validation. Prediction tools that utilize various algorithms 
to predict target sites can produce widely different results, indicating high levels of 
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false positives or non-predictable target sites. Candidate targets can also be 
identified through inhibition or overexpression of the miRNA of interest. Direct or 
downstream targets can then be inferred from miRNA effect on gene expression 
patterns, as measured by microarray or RNA-sequencing. Because the transcript is 
not always degraded by miRNA interaction [66], many targets can still be missed 
with these techniques. Therefore, predicted target regulation at the protein level 
must be verified with tools such as immunoblotting, IHC, or reverse phase protein 
array (RPPA). To validate bona-fide primary targets of a particular miRNA, a reporter 
assay can be used. This can be done by designing a “reporter plasmid” that contains 
an inserted piece of the gene containing the miRNA target site of the gene of 
interest, often located in the 3′ UTR, immediately downstream of a luciferase protein 
encoding sequence driven by a constitutive promoter. The recombinant reporter 
plasmid and miRNA of interest can then be co-transfected into a host cell, preferably 
one with low endogenous levels of the miRNA of interest that can be easily 
transfected in culture. Luciferase activity can then be measured 48 hours later. If the 
miRNA is functionally relevant and binds to the putative target site, synthesis of 
luciferase and its activity will be suppressed in the cells co-transfected with the 
reporter containing the 3′ UTR compared to cells containing the control reporter 
plasmid without the added insert containing the miRNA target site. Use of another 
vector containing a version of the miRNA binding sites in which the critical residues 
that allow the miRNA to bind is used to definitively demonstrate that binding of the 
miRNA is what is inhibiting luciferase activity. Alternatively, high-throughput 
sequencing of RNA isolated by crosslinking immunoprecipitation (HITS-CLIP) can 
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identify novel interaction sites of the miRNA directed Ago protein with target mRNAs 
[69]. This technique has successfully identified miRNAs that target mRNA in the 
three main breast cancer subtypes [70]. It is always best to test miRNA functionality 
through the use of multiple techniques because each has its own set of caveats. 
microRNA Roles in Development and Cancer 
The precise timing and tissue specificity of protein expression in many animal 
tissues is controlled in part by miRNAs. The first miRNAs discovered were shown to 
be regulators of developmental timing in C. elegans [71, 72]. Roles for several 
miRNAs have also been determined in mammary gland development. For example, 
Let-7 is involved in self renewing progenitor cells of the mouse mammary gland [73]. 
Another miRNA, miR-101a, regulates mammary epithelial cell proliferation by 
suppressing cyclooxygenase-2 expression [74]. miR-205 is highly expressed in stem 
cell-enriched populations of mouse mammary gland, suggesting a role in normal 
mammary stem cell maintenance [75]. The functional role of one miRNA as a proof 
of principle for other similarly expressed miRNAs during the secretory activation 
stage of mammary gland development is addressed in this dissertation. 
miRNAs are dysregulated in almost all human cancers [76], and breast 
cancer is no exception. In cancer, miRNAs can serve as oncogenes, where an 
aberrant overexpression contributes to the cancer phenotype. Some examples of 
oncogenes in breast cancer that have yielded a number of potential biomarkers and 
therapeutic targets include miR-9, miR-10b, miR-21, miR-27a, miR-29a, miR-96, 
miR-146a, miR-155, miR-181, miR-191, miR-196, miR-221/222, miR-272, miR-520c, 
and miR-589 [77-79]. miRNAs can also function as tumor suppressors, where a loss 
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or down-regulation contributes to the cancer phenotype. In breast cancer, some 
examples of tumor suppressors include miR-30a, miR-31, miR-34a, mir-125, miR-
126, miR-146a, miR-146b, miR-195, miR-200, miR-206, miR-221, and let-7 [77, 79-
83]. One of the most well categorized tumor suppressive miRNAs in breast cancer 
are the miR-200 family of miRNAs, which are known as the “guardian of the 
epithelial phenotype” by virtue of targeting and consequently repressing many genes 
not normally expressed in epithelial cells [84]. This miRNA family is highly expressed 
in normal, well differentiated epithelial cells, allowing them to be such by keeping off 
genes normally expressed in cells of mesenchymal or neuronal origin [85, 86]. Many 
carcinomas (derived from epithelial cells) undergo an EMT in which they acquire 
expression of these mesenchymal and neuronal genes to facilitate invasiveness and 
the ability to survive when detached from a basement membrane [87, 88]. In breast 
cancer, loss of miR-200c, allows for expression of the mesenchymal genes zinc 
finger E-box binding homeobox 1 (ZEB1) and ZEB2 [39, 85], which are not normally 
expressed in epithelial cells except during normal EMT when epithelial cells need to 
become mobile such as to form a neural crest or close the palate at the roof of the 
mouth [89, 90]. 
Whether a miRNA functions as a tumor suppressor or oncogene is entirely 
context dependent. For example, miR-9 is an oncogene in breast cancer [91, 92] 
and a tumor suppressor in colon cancer [93]. Another example is miR-130, which is 
an oncogene in nasopharyngeal carcinoma [94] and a tumor suppressor in breast 
cancer [95, 96]. Until more thorough investigation occurs, disparities can also be 
evident in miRNAs within the context of the same tissue. Take for example miR-205, 
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which has been categorized as both a tumor suppressor [75, 97-100] and an 
oncogene [101-103] in breast cancer. Breast cancer subtype, stage of 
tumorigenesis, and a host of other confounding variables may contribute to this 
confusion regarding miR-205 in breast cancer. 
Some miRNAs have been shown to be involved in cancer of the same tissue 
in which they play a normal developmental role. A prime example that is relevant to 
this dissertation is miR-150-5p, a 22 base-pair miRNA coded in an intergenic region 
of human chromosome 19 with an orthologous gene in chromosome 7 of the mouse. 
miR-150 is selectively expressed in mature resting B and T cells but not their 
progenitors [104], and premature overexpression of miR-150 blocks early B cell 
development [105]. miR-150 has been verified to control B cell differentiation in mice 
by targeting the myeloblastosis oncogene (Myb) [106], which is highly expressed in 
lymphocyte progenitors, downregulated during maturation, and again increased after 
activation of the mature cells [107]. There is an aberrant low expression of miR-150 
in a variety of hematological malignancies including diffuse large B cell lymphoma 
[108], Burkitt lymphoma [109], acute myeloid leukemia [110], and acute 
lymphoblastic leukemia [111] suggesting miR-150 is a tumor suppressor in this 
context. Indeed, the reduction of miR-150 allows for an inappropriate expression of 
MYB which has been shown to be elevated in and induce such cancers [112-115]. 
The developmental roles of miR-150, particularly in secretory activation, and its 





CONSTITUTIVE EXPRESSION OF MICRORNA-150 IN MAMMARY EPITHELIUM 
SUPRESSES SECRETORY ACTIVATION AND IMPAIRS DE NOVO 
LIPOGENESIS1 
Background 
As reviewed in Chapter I, mammary gland differentiation occurs during mid- 
to late- pregnancy in the mouse, when the MECs become competent to synthesize 
milk, but importantly, actual secretion is held in check until parturition when secretory 
activation is triggered [9, 116]. This trigger results in copious synthesis of milk 
comprised of milk proteins, sugars, and fats. Secretory activation may be regulated, 
in part, at the translational level by expression of miRNAs that attenuate protein 
synthesis until biosynthetic enzymes and secretory machinery are needed. Avril-
Sassen et.al. performed the first global expression array of miRNAs from whole 
mammary gland lysates throughout postnatal development and found that the three 
most populated miRNA expression clustering patterns shared a dramatic decline at 
the transition between pregnancy and lactation [117]. 
Although the Caldas group identified distinct patterns of miRNA expression 
during mammary gland development, it is possible that other cell types such as 
mammary adipose, lymphatic, and immune cells [118] contributed to the patterns 
observed. Therefore, to identify MEC-specific miRNAs with the potential to regulate 
secretory activation and the biosynthetic processes of milk production, we performed 
simultaneous miRNA and mRNA profiling on isolated MECs from mice at pregnancy 
                                            
1 The majority of this chapter was accepted for publication in Development. 
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day 14 (P14) and lactation day 2 (L2). P14 was chosen to represent a timepoint after 
alveologenesis and just before most of the lipid synthesis genes are transcribed 
during secretory differentiation (Fig. A.1) [9]. L2 was chosen to represent post 
secretory activation. Furthermore, both of these timepoints (P14 and L2) represent 
when the bulk of differentially expressed miRNAs are high during pregnancy and low 
at lactation as shown by the Caldas group [117]. From the profiling data, I identified 
a number of miRNAs that decrease in unison between P14 and L2, including miR-
150-5p, which had the largest fold decrease. The coordinated decrease in multiple 
miRNAs was coincident with the reciprocal up-regulation of numerous metabolic 
pathways critical for lactation, including lipid modification and fatty acid synthesis. To 
test the functional involvement of miR-150 in secretory activation, we used 
transgenic mice that constitutively express miR-150 driven by the whey acidic 
protein (WAP) promoter in MECs throughout mid-pregnancy and lactation. My 
finding that constitutive expression of miR-150 leads to lactation deficiency and pup 
mortality suggests that the decline in miR-150-5p expression in MECs at late 
pregnancy contributes to secretory activation, induction of lipogenic mRNA and 
proteins, and robust activation of de novo lipid synthesis in lactation.  
Materials and Methods 
Mice 
CD1 background mice were purchased from Taconic (Germantown, NY). 
Stop-150fl/fl in C57BL/6 background were kindly provided by Changchun Xiao, The 
Scripps Research Institute [106]. WAP-Cre+ transgenic mice in FVB were originally 
generated as described [119]. Eight week old control females (WAP-Cre+; Stop-150-) 
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or bitransgenic females with constitutive expression of miR-150 at late pregnancy 
and throughout lactation (WAP-Cre+; Stop-150fl/fl) were impregnated by wild type 
males. Pregnancy day 1 (P1) was identified as the first day a postcoital plug was 
observed. Lactation day 1 (L1) was identified as the first day litters were present. 
Mammary glands were harvested from dams at P14, pregnancy day 18 (P18), and 
L2. Pup survival data was collected from postnatal day 3 (PND3) and every other 
day through lactation day 15 for first litters only. Initial litter size was defined as the 
total number of pups present at PND3. In fostering experiments, only litters born to 
control dams within 1 day of the biological litter were used as foster litters starting at 
PND3. All animal procedures were approved by the Institutional Animal Care and 
Use Committee of the University of Colorado Anschutz Medical Campus. 
MEC isolation 
Adipose-depleted mouse MECs were isolated from the upper inguinal 
mammary glands as described [118] with modifications. Specifically, after removal of 
lymph nodes, the mammary glands were removed, minced, and digested with 1 
mg/mL collagenase type 1 (Worthington Biochemical Corporation, LS004196) in 
Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12 (HyClone, 11330-032), for 
80 min in a 37°C rotor. Collagenase was then quenched with 0.5% fetal bovine 
serum, and the digested cell suspension was pelleted by centrifugation. Erythrocytes 
were then removed by successive washes of the cell pellet in Dulbecco’s phosphate-
buffered saline with calcium and magnesium (Hyclone SH30264.01) followed by 2-
second centrifugations at 1500 rpm until pellet was no longer red. Cell pellets were 




Total RNA was isolated from MECs using Trizol RNAeasy solution (Thermo 
Fisher Scientific, Waltham, MA, USA) and purified by Qiagen miRNA columns 
(Qiagen, Venlo, Netherlands). RNA concentration and purity were assessed in 
Applied Biosytems Bioanalyzer 2100 (Thermo Fisher Scientific). 
Microarray hybridization 
One µg of total RNA from each sample was labelled with FlashTag Biotin 
RNA Labeling kit (Genisphere, Hatfield, PA, USA) and hybridized onto GeneChip 
Mouse Gene 1.0 ST, GeneChip miRNA 1.0 ST, and GeneChip Mouse 
Transcriptome Array 1.0 (Affymetrix, Santa Clara, CA, USA) according to the 
manufacturer’s recommendations and performed in the University of Colorado 
Cancer Center Microarray Core Facility. The raw data for all three arrays are 
available at http://www.ncbi.nlm.nih.gov/geo under series records GSE87584 and 
GSE80666. 
MicroRNA microarray data analysis 
Data were extracted from the images, quantile normalized, summarized 
(median polish) and log2-transformed with miRNA QC tool software (Affymetrix). 
Data from mouse miRNAs were imported into GeneSpring GX10 (Agilent 
Technologies, Santa Clara, CA, USA) by creating a custom miRNA experiment, and 
differentially expressed miRNAs were identified using unpaired t-test. The p-values 
were corrected by multiple testing using Benjamini-Hochberg False Discovery Rate 




Gene expression data analysis 
Affymetrix CEL files from all samples were loaded on to Genespring GX10. 
Signal intensities for all probe sets were obtained using Robust Multichip Averaging 
summarization algorithm, involving three steps – background correction, quantile 
normalization and probe summarization (median polish). Quality control was 
performed by principal component analysis to identify outliers. Differentially 
expressed probe sets between P14 and L2 were identified by performing an 
unpaired t-test to obtain raw p-values, which were subsequently corrected by 
multiple testing using BH-FDR method. A 5% FDR cut-off was chosen to identify 
differentially expressed probe sets. 
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) 
cDNA was synthesized using Taqman MicroRNA Reverse Transcription kit 
(Thermo Fisher Scientific) and miRNA-specific RT primers as per manufacturer’s 
recommendations. PCR for each miRNA was performed using specific Taqman 
MicroRNA probe and Absolute Fast QPCR Low Rox mix (2×) (Thermo Fisher 
Scientific) or TaqMan Universal PCR Master Mix No AmpErase UNG (2×) (Thermo 
Fisher Scientific). Quantification of miRNA was determined by calculating the relative 
copy number of each miRNA or the comparative threshold cycle (Ct) method. To 
estimate relative copy number, a standard curve was run using five four-fold 
dilutions of a P14 sample in duplicates. To calculate 2-ΔΔCt, the Ct values for RNAU6 
were subtracted from Ct values of the miRNA to achieve the ΔCt value. The ΔCt of a 
control sample was then subtracted from each ΔCt to achieve the relative miRNA 
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levels (ΔΔCt). Fold change is calculated (2
-ΔΔCt). Statistical differences in miRNA 
expression between P14 and L2 samples were analyzed by t-test. 
MicroRNA in situ hybridization (ISH) 
Lower thoracic glands were fixed in 10% neutral buffered formalin. Tissue 
processing and paraffin embedding were performed by the UC Denver Histology 
Shared Resource. Sections of mammary glands were analyzed by ISH as described 
in [120]. A hybridization temperature of 53°C and miRCURY LNA microRNA 
Detection Probes pre-labeled with double digoxigenin and complementary to mature 
miR-150-5p (CACTGGTACAAGGGTTGGGAGA) (Exiqon, Copenhagen, Denmark) 
were used.  
Microscopy 
Representative images of ISH, IHC, and Hematoxylin and eosin (H&E) slides 
were taken using an Olympus BX40 microscope (Center Valley, PA, USA) with a 
SPOT Insight Mosaic 4.2 camera and software (Diagnostic Instruments, Inc., 
Sterling Heights, MI, USA). 
Canonical pathway analysis 
Canonical pathway analysis was calculated using Ingenuity Pathway Analysis 
(IPA) (Qiagen). Significance was calculated by Fisher’s exact test right-tailed. The 
significance indicates the probability of association of altered molecules in the 
dataset with the pathway by random chance alone. The percent altered genes 
indicate the number of statistically significantly altered genes in the pathway divided 
by the total number of genes that make up that pathway. 
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microRNA target predictions 
Targets of  mmu-miR-150-5p were bioinformatically predicted using 
TargetScan Mouse v7.1, TargetScan Human v7.0 [61], and RNA22 v2.0 [121]. 
Immunohistochemistry 
Sections of paraffin-embedded mammary glands were cut at 4 μm and 
deparaffinized in xylene, rehydrated with a series of graded ethanols, and subjected 
to heat induced epitope retrieval in 10 mM citrate buffer, pH 6.0. Endogenous 
peroxidase was blocked, and slides were treated with 10% normal goat serum. 
Primary antibodies used were anti-fatty acid synthase (FASN) (Abcam ab22759, 
Cambridge, UK, 1:8000 and BD Biosciences 610962, Franklin Lakes, NJ, USA, 
1:3,200), anti-MYB (Millipore 05-175, Billerica, MA, USA, 1:50), anti-adipophilin 
(Fitzgerald 20-AP002, Acton, MA, USA, 1:1600), anti-acetyl-CoA carboxylase alpha 
(ACACA) (Cell Signaling Technology 3676, Danvers, MA, USA, 1:1,600) and anti-
cleaved caspase 3 (CC3) (Cell Signaling Technology 9661, 1:1,600). Primary 
antibody detection was performed with either EnVision+ System-HRP labeled 
polymer secondary (Agilent Technologies K4001,K4003) or secondary antibody 
labeled with biotin (Dako/Agilent Technologies E0433, Carpinteria, CA; Jackson 
Immuno Research, West Grove, PA, USA) followed by incubation with streptavidin-
HRP (Dako) and 3, 3′-diaminobenzidine (Dako) detection. For CC3 staining, three 
separate 100× fields of each slide  were analyzed with ImageJ (National Institutes of 
Health, Bethesda, MD, USA). Color threshold was adjusted manually (Red Green 
Blue (RGB) for positive staining nuclei, and Hue Saturation Brightness (HSB) for 




Hematoxylin and eosin staining 
H&E stains were purchased from Anatech Ltd. and used per the 
manufacturer's instructions. Three separate 100× fields of each slide were analyzed. 
Nuclei were counted manually for each field. Alveolar pixel area was quantified using 
ImageJ (National Institutes of Health) by first subtracting non-epithelial tissue then 
adjusting a color threshold using HSB color space to include total epithelium. 
Nuclear density was calculated by dividing nuclei counts with the HSB area. 
RPPA 
RPPA printing and analysis of MEC samples was conducted as previously 
described [122-124]. Before use for RPPA analysis, antibody specificity was 
confirmed by immunoblot and analysis, as previously described [124].  
Immunoblot 
Protein resolved by polyacrylamide gel electrophoresis  (20 µg) was 
transferred to Immobilon-FL membranes (Millipore Continental Water Systems, 
Bedford, MA, USA). The membranes were blocked with 5% milk in PBS, probed with 
primary antibodies overnight at 4°C, washed and incubated with appropriate Alexa 
Fluor secondary antibody (Thermo Fisher Scientific). The primary antibodies used 
were anti-phospho-signal transducer and activator of transcription 5 (pSTAT5) 
(Tyr694) (Cell Signaling Technology, 9351), anti-STAT5B (Millipore, 06-554), anti-
STAT5A (Millipore, 06-968), anti-WAP (Santa Cruz, 398276), anti-FASN (Cell 
Signaling Technology, 9363), anti-ACACA (Cell Signaling Technology, 3676), anti-
oleoyl-ACP hydrolase (OLAH) (generous gift of Dr. Stuart Smith, Children’s Hospital 
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Oakland Research Institute, Oakland CA, USA), and anti-α-tubulin loading control 
(Sigma, T5168). Protein from each MEC sample was detected by immunoblot using 
Odyssey infrared imager (LI-COR Biosciences, Lincoln, NE, USA). 







Oligo primers for cloning of mouse 3′ UTR for Stat5b 
For Stat5b-3′-UTR-WT site 1: 
forward 5′-GTAAATTATTTATTGGGAGATGAGTTTTTAAAAGCTGCTG-3′ 
reverse 5′- CTCATCTCCCAATAAATAATTTACTACACAGGAGTTTG-3′ 
For Stat5b-3′-UTR-mut site 1: 
forward 5′-GTAAATTATTTACGAGGCGATGAGTTTTTAAAAGCTGCTG-3′ 
reverse 5′- CTCATCGCCTCGTAAATAATTTACTACACAGGAGTTTG-3′ 
For Stat5b-3′-UTR-WT site 2: 
forward 5′-GTACCTGGACATGGGAGAGGTTTTTAACTGGAAAGTG-3′ 
reverse 5′-GTTAAAAACCTCTCCCATGTCCAGGTACACCCTCAG-3′ 





Construction of Fasn and Stat5b-3′ UTR-Luciferase reporters and luciferase reporter 
assay 
The 3′ UTR DNA fragments of mouse Fasn (1896 bp, NM_007988) and 
Stat5b (2518 bp, NM_001113563) containing the putative miR-150-5p target sites 
were amplified by PCR from mouse genomic DNA and cloned into the SacI/XhoI 
digested pmirGLO vector downstream of the firefly luciferase cDNA sequence 
(Promega), resulting in the generation of Fasn-3′-UTR-luc and Stat5b-3′-UTR-luc 
plasmids. These plasmids were used as a template to generate DNA fragments with 
mutated miR-150-5p targeting sites (Fasn-3′-UTR-mut, Stat5b-3′-UTR-luc-mut) by 
using mutated oligos. DNA sequencing verified the sequence of both plasmids.  
Murine mammary tumor 4T-1 cells were plated at 1×105 cells per well in a 24-
well plate. The next day, cells were co-transfected with 50 nM of control RNA or 
miR-150 mimic (Ambion, Austin, TX, USA) together with 0.5 µg of aforementioned 
pmirGLO plasmids containing wild type or mutated putative target sites using 
lipofectamine 2000 (Thermo Fisher Scientific). Cells were lysed 48 hours later and 
the dual-luciferase reporter assay system (Promega) was used to measure 
luciferase activity according to manufacturer’s instructions. 
Total lipid extraction 
Because of the low milk yield from WAP-Cre+; Stop-150fl/fl mammary glands 
compared to controls, even after administration of a bolus of oxytocin, lipids were 
extracted from isolated MECs. HPLC grade reagents were purchased from Sigma-
Aldrich (St. Louis, MO). Total lipid extraction was performed as previously described 
[125] with modifications. Briefly, 7-20 mg of MEC pellet was suspended in 250 μL of 
25 
 
100 mM potassium phosphate buffer pH 7.2, mixed by inversion, acidified with 20 μL 
of 1 M HCl, 500 μL of 100% methanol was added, and samples were homogenized 
by rotor/stator. Lysates were cleared by centrifugation and supernatant transferred 
to glass tubes. Total lipids were extracted with 2 × 1 mL of isooctane/ethyl acetate 
3:1 v/v and vortexed vigorously. The organic phase was collected and taken to 
dryness by evaporation under nitrogen gas at 40°C, and samples were resuspended 
in 250 μL of isooctane. 
Quantification of MEC triacylglycerol and fatty acids 
50 μL of isooctane suspended total lipid was taken to dryness under nitrogen 
gas, samples were resuspended in 200 μL dichloromethane that contained 15 μL of 
a 10% nonaethylene glycol monododecyl ether (Sigma Aldrich, St. Louis, MO) 
dissolved in dichloromethane (wt/vol). Samples were incubated for 5 min at 25°C 
and taken to dryness at 40°C for 25 minutes to ensure organic solvent was 
completely evaporated. Pellets contained triglyceride/nonionic surfactant complexes, 
to which 200 μL of reverse osmosis water was carefully added without mixing and 
incubated at 40°C for 10 min and followed by a gentle vortex. A standard regression 
curve was made using 80 nmol of tripalmitin (Sigma Aldrich, St. Louis MO) 
combined with 25 μL of 10% nonaethylene glycol monododecyl ether in 
dichloromethane (wt/vol), incubated and dried as above, suspended in 100 μL of 
reverse osmosis water, and dilutions of 20, 10, 5, 2.5, 1.25, 0.625, and 0.3125 nmol 
tripalmitin were used. Total triacylglycerol (TAG) from the organic fraction was 
quantified relative to known tripalmitin standard using a modified colorimetric assay 
[126] and are expressed as mM concentrations. Triglyceride Reagent and Free 
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Glycerol Reagent were purchased from Sigma Aldrich (St. Louis, MO) and diluted 
according to the manufacturer’s instructions. 
Gas chromatography-mass spectrometry 
Amounts of fatty acid in MEC were analyzed by Gas Chromatography-Mass 
Spectrometry (GC-MS). Blended stable isotope internal standards containing 100 ng 
each of [D]3-decanoic acid, [D]3-lauric acid, [D]3-myristic acid, 1,2,3,4-[13C]4-
palmitic acid, [D]3-stearic acid, [D]4-oleic acid, [D]8-arachidonic acid, and [D]5-
docosahexanoic acid (purchased from Sigma-Aldrich; Cambridge Isotopes 
(Andover, MA); or Cayman Chemical Co. (Ann Arbor, MI) with 99 atom % 13C and 
99 atom % D, respectively) were added to the volume of each sample representing 5 
nmoles of MEC TAG as quantified above. Samples were taken to dryness under N2 
gas, suspended in 0.5 mL 100% methanol, and were saponified at 45°C for 1 h by 
adding 0.5 mL of 1M sodium hydroxide mixing at 20 min intervals. Samples were 
acidified with 0.525 mL of 1 M HCl, vortexed vigorously; fatty acids were extracted 
twice with 1.0 mL of isooctane, and taken to dryness under N2 gas. Saponified fatty 
acids were derivatized at room temperature for 30 min by addition of 30 µL of 1% 
pentafluorobenzyl bromide in acetonitrile and 30 µL of 1% N,N-diisopropylethylamine 
in acetonitrile according to [125], after which the samples were taken to dryness 
under N2 gas. The resulting pentafluorobenzyl fatty acid esters were suspended in 




Between late pregnancy and early lactation, the majority of differentially expressed 
miRNAs show decreased expression, with miR-150-5p demonstrating the highest 
fold decrease.  
To identify candidate miRNAs that regulate secretory activation specifically in 
MECs following functional development, simultaneous global mRNA and mature 
miRNA profiling was performed. Thirty-two differentially expressed miRNAs 
displayed a ≥ 2-fold change between P14 and L2 (Fig. 2.1A), and the majority 
(~80%) were reduced. The observed decreases include miR-150-5p (7.64-fold, 
p=0.01), miR-17-5p (2.26-fold, p=0.00005), and miR-425-5p (2.53-fold, p=0.002), 
which were validated by qRT-PCR (Fig. 2.1B). In addition, MEC specific decreased 
expression of miR-150-5p in mammary epithelium at L2 compared to P14 was 
verified by in situ hybridization (ISH) (Fig. 2.1C). 
The decline of miR-150-5p at L2 coincides with increased predicted lipogenic mRNA 
targets.  
MEC specific mRNAs were profiled by microarray, and transcripts significantly 
different between P14 and L2 were identified using unpaired t-test. IPA on 
upregulated transcripts identified key pathways involved in secretory activation, 
particularly cholesterol and lipid biosynthesis (Fig. A.2), were increased between 
pregnancy and lactation, as would be expected. Twenty-three of the 25 significantly 
decreased miRNAs between P14 and L2 (Fig. 2.1A) were predicted to target 




Figure 2.1. Between late pregnancy and early lactation, the majority of 
differentially expressed miRNAs show decreased expression, with miR-150-5p 


















































Figure 2.1. Between late pregnancy and early lactation, the majority of 
differentially expressed miRNAs show decreased expression, with miR-150-5p 
demonstrating the highest fold decrease. (A) Affymetrix GeneChip miRNA 1.0 ST 
array heatmap depicting normalized signal values of miRNAs with fold change 
greater than two from CD1 mouse MECs at P14 and L2 (4 mice per time point). . 
Significant miRNAs sorted from most decreased in fold change at the top to most 
increased at the bottom. Array was analyzed by Palani Ramanathan. (B) Changes in 
the expression of miRNAs revealed by miRNA array (top), verified by qRT-PCR 
(bottom). Shown are mean±s.d., n=4, unpaired t-test. Comparison of fold change 
(P14/L2) between methods is shown in the table. PCR was performed by Palani 
Ramanathan. (C) ISH analysis for mature miR-150-5p in mammary glands at L2 
compared to P14 (3 mice per time point). Positive control (RNAU6 probe) and 





L2 and included key members of the de novo fatty acid synthesis pathways as well 
as several fatty acid desaturase genes (Table 2.1). Notably, miR-150-5p is predicted 
to target more lipid synthesis genes than most other miRNAs (Table 2.1). There 
were 242 TargetScan predicted miR-150-5p targets significantly upregulated by at 
least 1.5 fold or greater at L2 versus P14 (top 3 fold shown in Fig. 2.2A). Because 
Myb is a target of miR-150-5p [106], MYB protein was examined by IHC. Although 
the array data found Myb mRNA to be unaltered, MYB protein was increased in 
mammary epithelium at L2 compared to P14 (Fig 2.2B top), suggesting that miR-
150-5p suppresses Myb through translational repression as opposed to the other 
mechanisms that would result in degradation of Myb transcript. Since Fasn was 
increased between P14 and L2 and was a predicted target, the protein level of 
FASN was also confirmed by IHC (Fig. 2.2B bottom). IPA analysis of the 242 
upregulated predicted targets of miR-150-5p revealed that lipid and cholesterol 
biosynthesis pathways at secretory activation were among the most significantly 
enhanced pathways correlated with the decline in miR-150-5p at L2 (Fig. 2.2C). 
Constitutive expression of miR-150 in mammary epithelium throughout lactation 
leads to a severe lactation defect.  
The decrease in miRNAs such as miR-150-5p at L2 might allow for maximal 
and accurately timed expression of proteins important for secretory activation. To 
test this possibility, we used a transgenic mouse model designed to override the 
natural decline in miR-150 by constitutive expression of miR-150 in the mammary 
epithelium. WAP-Cre+ transgenic mice were crossed with Rosa-26-flox-Stop-flox-
miR-150fl/- (Stop-150fl/-) transgenic mice (Fig. 2.3A,B). Sustained expression of 
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Table 2.1. Significantly decreased miRNAs predicted to target lipid synthesis 
genes that increased between P14 and L2. 
 
Significant downregulated miRNAs are listed on the left, sorted from large to small 
fold change (FC) indicated in parenthesis. Genes involved in lipid synthesis that 
were TargetScan predicted targets of each miRNA are listed on the right. Numbers 
in parenthesis indicate fold increase of gene expression at L2 compared to P14 in 
the Affymetrix Mouse Gene 1.0 ST array. miRNAs that are part of the miR-17/92 
cluster are in bold. 
miRNA (-FC) Predicted Gene Targets (+FC)
miR-150-5p (7.6) Olah (10.7), Fasn (6.6), Fads1 (5.5), Elovl5 (4.5), Elovl6 (4.0), Elovl1 (3.7)
miR-342-3p (4.4) Me1 (9.6), Scd2 (7.2), Fasn (6.6), Fads2 (4.2), Elovl6 (4.0)
miR-20b-5p (3.8) Insig1 (12.1), Pank3 (3.9)
miR-146a-5p (2.9) Fads2 (4.2)
miR-361-5p (2.8) Fasn (6.6), Scd1 (5.9), Elovl6 (4.0), Pank3 (3.9)
miR-342-5p (2.7) Scd2 (7.2), Acly (4.9)
miR-191-5p (2.6) Me1 (9.6), Elovl6 (4.0)
miR-425-5p (2.5) Lpl (7.8), Fasn (6.6), Elovl5 (4.5), Thrsp (4.0), Pank3 (3.9), Tpi1 (1.5)
miR-155-5p (2.5) Lpl (7.8), Fads2 (4.2), Pank3 (3.9)
miR-18a-5p (2.5) Scd2 (7.2), Acaca (6.6), Fads1 (5.5), Fads2 (4.2), Elovl1 (3.7)
miR-106a-5p (2.5) Insig1 (12.1), Pank3 (3.9)
miR-17-3p (2.4) Acacb (8.8), Fasn (6.6), Fads1 (5.5), Acly (4.9), Pank3 (3.9)
miR-130b-3p (2.3) Slc25a1 (10.9), Acacb (8.8), Elovl6 (4.0)
miR-92a-3p (2.3) Insig1 (12.1), Pank3 (3.9)
miR-17-5p (2.3) Insig1 (12.1), Elovl6 (4.0), Pank3 (3.9)
miR-150-3p (2.1) Insig1 (12.1), Acaca (6.6), Fads1 (5.5), Elovl6 (4.0), Pank3 (3.9) 
miR-29a-3p (2.1) Insig1 (12.1), Lpl (7.8), Scd1 (5.9), Fads1 (5.5)
miR-20a-5p (2.1) Insig1 (12.1), Pank3 (3.9)
miR-106b-5p (2.1) Pank3 (3.9), Elovl6 (4.0)
miR-15b-5p (2.1) Me1 (9.6), Fasn (6.6), Scd1 (5.9), Fads1 (5.5), Slc2a1 (3.3)
miR-185-5p (2.1) Fads1 (5.5), Agpat1 (2.1), Elovl6 (4.0)
miR-106b-3p (2.0) Insig1 (12.1), Elovl6 (4.0), Pank3 (3.9)




Figure 2.2. The decline of miR-150-5p at L2 coincides with increased predicted 


































































Figure 2.2. The decline of miR-150-5p at L2 coincides with increased predicted 
lipogenic mRNA targets. (A) Affymetrix GeneChip Mouse Gene 1.0 ST array 
heatmap depicting normalized signal values of miR-150-5p predicted targets from 
CD1 mouse MECs at P14 and L2 (4 mice per time point). Significant mRNAs sorted 
from most increased in fold change at the top to least increased at the bottom with a 
3 fold cutoff due to space constraints. Array was analyzed by Palani Ramanathan. 
(B) IHC for validated target MYB and predicted target FASN (Abcam, ab22759) at 
P14 versus L2 (3 mice per time point), scale bar = 20 μm. (C) Altered pathways 
based only on predicted miR-150-5p targets that were increased at L2 compared to 
P14, inverse to the decrease in miR-150-5p expression. Pathways were sorted in 
order of decreasing statistical significance (-log of p-value), represented by black 
bars with values indicated on the top axis. Grey line represents the % altered genes 
in each pathway with values indicated on the bottom axis. Only the top 13 
significantly altered canonical pathways are displayed due to space constraints. IPA 




Figure 2.3. Constitutive expression of miR-150 in mammary epithelium 
throughout lactation leads to a severe lactation defect.  
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Figure 2.3. Constitutive expression of miR-150 in mammary epithelium 
throughout lactation leads to a severe lactation defect. (A) Structures of the 
WAP-Cre and Stop-150 transgenes. (B) Mice with constitutive expression of miR-
150-5p in the mammary epithelium throughout lactation (genotype WAP-Cre+; Stop-
150fl/fl) along with littermate controls (genotype WAP-Cre+; Stop-150-) were 
generated from breeding STOP-150fl/- mice with WAP-Cre+ mice as indicated in the 
schematic. (C) L2 MECs from WAP-Cre+; Stop-150fl/fl mice showed significant 
increase in miR-150-5p expression compared to MECs from controls. TaqMan qRT-
PCR was used to quantify miR-150-5p expression normalized to RNAU6. Error bars 
represent standard deviation, n=10, unpaired t-test. (D) Biological and fostered pups 
nursed by WAP-Cre+; Stop-150fl/fl dams showed significant decrease in survival 
compared to those nursed by control mice. Kaplan-Meier survival plots of biological 
and fostered pups nursed by the indicated dam genotypes, n=number of first time 
litters included in the data, log-rank (Mantel-Cox) test. (E) Photos from 
representative surviving pups at L2, nursed by indicated genotypes, mm increments 
are shown on ruler behind each pup.  
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mature miR-150-5p following secretory activation in L2 MECs from WAP-Cre+; Stop-
150fl/fl mice was confirmed by qRT-PCR (Fig. 2.3C). To ensure that the miRNA 
processing machinery was not overburdened by constitutive synthesis of miR-150-
5p, we quantified miR-146b-5p, a miRNA that increased at L2 compared to P14 in 
wild-type mice (Fig. 2.1A). Constitutive expression of miR-150-5p did not affect 
levels of miR-146b-5p (Fig. A.3).  
Compared to offspring nursed by control dams (WAP-Cre+; Stop-150-), pups 
nursed by WAP-Cre+; Stop-150fl/fl dams had significantly decreased survival by 
PND3, that continued to diminish throughout lactation (Fig. 2.3D top). Surrogate 
litters from control dams confirmed the lactation defect persisted beyond PND3 as 
surrogate mortality was also significantly higher when nursed by WAP-Cre+; Stop-
150fl/fl dams relative to control dams (Fig. 2.3D bottom). Additional evidence of the 
lactation defect in dams constitutively expressing miR-150 was observed in the milk 
spots of surviving pups at PND2, which were notably smaller in pups nursed by 
WAP-Cre+; Stop-150fl/fl dams (Fig. 2.3E). These data indicate constitutive expression 
of miR-150-5p in mammary epithelium results in a severe lactation deficiency with 
death of over 50% of offspring by PND3. 
Constitutive expression of miR-150 reduced alveolar density at L2 and decreased 
multiple proteins including total and phosphorylated STAT5B.  
To understand lactation defects at the cellular level, histological mammary 
gland sections from P18 and L2 were evaluated for morphological changes. 
Mammary glands from WAP-Cre+; Stop-150fl/fl mice had no difference in alveolar 
density as late into pregnancy as P18 when compared to that from control mice (Fig. 
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2.4A). Furthermore, IHC for the lipid droplet binding protein adipophilin indicated that 
WAP-Cre+; Stop-150fl/fl mice have equivalent lipid droplet size and abundance at 
P18 (Fig. A.4). In contrast, there was decreased alveolar density between genotypes 
at L2 (Fig. 2.4A).  
RPPA was used to examine a variety of total and phosphorylated signal 
transduction proteins in MEC lysates from control and WAP-Cre+; Stop-150fl/fl mice 
at both P14 and L2 (Fig. 2.4B). The majority of proteins differentially expressed 
between genotypes, including the phosphorylated forms of janus kinase 1 (JAK1) 
(Y1022/Y1023), FAK (Y397), and ER alpha (S118), were decreased by constitutive 
expression of miR-150 only at L2 (Fig. 2.4B). However, miR-150 had no 
significant effect on proteins at P14 (Fig. 2.4B).  
To rexplore the cause of morphological changes observed in the bitransgenic 
mice at L2 (Fig 2.4A), histological sections were quantified for nuclei count and area 
(Fig 2.4C). Because there was no difference in nuclei count (Fig 2.4C left), but 
epithelial area normalized to nuclei count was significantly reduced (p=0.02) (Fig 
2.4C right), the difference in observed alveolar density is due to the epithelium in 
control mice becoming distended with milk, while epithelium in bitransgenic mice are 
much less distended.  
PRLR signaling through mediated through JAK2 and STAT5 is essential for 
lactation [127]. Both total STAT5B (a TargetScan predicted target of miR-150-5p) 
and pSTAT5 were significantly reduced in L2 MECs from WAP-Cre+; Stop-150fl/fl 




Figure 2.4. Constitutive expression of miR-150 reduced alveolar density at L2 
and decreased multiple proteins including total and phosphorylated STAT5B. 
  

































Estrogen Receptor total* 
ATP Citrate Lyase S454
GAB1 Y627*
PAK1 S199/S204-PAK2 S192/S197*






































Figure 2.4. Constitutive expression of miR-150 reduced alveolar density at L2 
and decreased multiple proteins including total and phosphorylated STAT5B. 
(A) Mammary glands from WAP-Cre+; Stop-150fl/fl mice showed similar mammary 
alveoli density to control mice at P18, but reduced density at L2 compared to 
controls. H&E staining on mammary gland sections from mice at P18 and L2 (3 mice 
per time point and genotype), scale bar = 200μm. (B) Heatmap depicting RPPA 
normalized signal values of proteins significantly differentially expressed in L2 MECs 
from both genotypes (4 mice per genotype). Significant protein differences at L2 
(p<0.05) sorted by most decreased in fold change at the top and most increased fold 
change at the bottom. Asterisks indicate predicted targets of miR-150-5p based on 
TargetScan and RNA22. Protein levels in MECs at P14 from both genotypes also 
shown (3 mice per genotype). RPPA was performed at George Mason University. 
(C) Quantification of nuclei count on H&E staining on mammary gland sections from 
mice at L2 (3 mice per genotype). Shown are mean±s.d., unpaired t-test. 
Quantification was performed by Nicole Spoelstra. (D) STAT5B expression and 
STAT5 activation were impaired in L2 MECs from WAP-Cre+; Stop-150fl/fl mice 
compared to controls. Immunoblot analysis of MEC lysate using antibodies against 
indicated proteins and α-tubulin as a loading control, 5 mice per genotype, 
quantification for pSTAT5 and STAT5B excludes lane 4 of the control samples. 
Shown are mean±s.d., unpaired t-test. (E). 4T-1 cells were co-transfected with non-
specific negative control (NC) or miR-150-5p mimic (miR-150) together with 
pmirGLO The predicted miR-150-5p target sites in positions 1566-1573 and 1984-
1990 of mouse Stat5b-3′ UTR are shown. 4T-1 cells were co-transfected with NC or 
miR-150-5p mimic (miR-150) together with pmirGLO Stat5b-3′ UTR-WT or Stat5b-3′ 
UTR-mut plasmids. Luciferase assay was performed. Shown are mean±s.d., n=4, 
unpaired t-test. Similar result was seen from 3 independent experiments. Luciferase 
reporter assays were performed by Hongwei Gao and Shang Chen. (F) Mammary 
glands from WAP-Cre+; Stop-150fl/fl mice showed significant increase in cell death 
during early lactation compared to controls. Quantification of cleaved caspase 3 IHC 
on mammary glands from mice with indicated genotypes at lactation day 2, (5 




ability of miR-150-5p to target the Stat5b 3′ UTR was tested with a Stat5b-3′ UTR-
luciferase reporter containing the predicted miR-150-5p binding sites (Fig. 2.4E). Co-
transfection of miR-150 mimic resulted in a significant decrease in luciferase reporter 
activity with the wt plasmid but not with the Stat5b-3′-UTR-mut plasmid, indicating 
miR-150 is a bona fide target of mouse STAT5B, acting on the 3′ UTR of Stat5b 
containing the predicted binding sites (Fig. 2.4E). Importantly, activated and total 
JAK2 were similar in L2 MECs from WAP-Cre+; Stop-150fl/fl mice compared to 
controls, suggesting there was normal PRLR activation upstream of STAT5 (Fig. 
A.5). Thus, my data indicate that targeted reduction of STAT5B, due to constitutive 
expression of miR-150, might impair secretory activation specifically through 
reduced STAT5B activity. 
Because STAT5 contributes to survival of differentiated mammary epithelium 
[128], cell death was investigated by CC3 IHC performed on tissue sections of L2 
mammary glands from WAP-Cre+; Stop-150fl/fl mice. Although less than 0.2% of 
MECs were CC3 positive, CC3 staining was significantly higher in mammary glands 
from WAP-Cre+; Stop-150fl/fl mice compared to controls (Fig. 2.4F), indicating that 
constitutive expression of miR-150 caused some increased cell death in mammary 
epithelium.  
Lipid and cholesterol synthesis genes are preferentially reduced by constitutive 
expression of miR-150.  
Global mRNA profiling identified significant gene expression changes due to 
constitutive expression of miR-150 in MECs. In agreement with the bioinformatics 
predictions shown in Fig. 2.2C, more than half of the genes involved in de novo lipid 
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and cholesterol synthesis had a ≥ 2-fold decrease due to constitutive expression of 
miR-150 at L2 (Fig. 2.5). Of the 22 listed lipid and cholesterol synthesis genes with a 
≥ 2-fold decrease, all but two are predicted to be direct targets of miR-150 
(TargetScan and RNA22). Notably, these predicted targets include the primary 
enzymes of the de novo fatty acid synthesis pathway, including ATP citrate lyase 
(Acly) [129], Acaca (both isoforms) [130], Fasn [131], and thyroid hormone 
responsive protein spot 14 (Thrsp) [125]. Further, mitochondrial citrate transporter 
(Slc25a1), a gene required to shuttle substrate into the de novo fatty acid synthesis 
pathway [132] also decreased. Transcripts of genes that modify fatty acids including 
stearoyl-CoA desaturase 1 (Scd1), fatty acid elongases (Elovl5 and Elovl6), and the 
fatty acid desaturase (Fads1) were also decreased by miR-150 expression. 
FASN, ACACA and OLAH, all involved in de novo lipid synthesis, are suppressed by 
constitutive expression of miR-150.  
FASN is absolutely essential in mammals to synthesize de novo fatty acids 
from acetyl-CoA and malonyl-CoA substrates [131]. Because Fasn and Acaca, 
which encodes the enzyme supplying substrate to FASN, decreased significantly at 
L2 in mice with constitutively expressed miR-150 (Fig. 2.5), protein levels were 
evaluated by immunoblot and IHC. Immunoblot analysis indicated an approximate 
85% (p=0.0001) suppression of FASN protein in L2 MEC lysates from WAP-Cre+; 
Stop-150fl/fl mice compared to control MECs (Fig. 2.6A). In addition, IHC analysis 
revealed that while FASN levels in the epithelium of control mice increased 
dramatically from P14 to L2 (Fig. 2.6B top), FASN was inhibited at L2 in WAP-




Figure 2.5. Lipid and cholesterol synthesis genes are preferentially reduced by 
constitutive expression of miR-150. Negative fold change values for genes critical 
to lactation were calculated from the Affymetrix GeneChip Mouse Transcriptome 
Array 1.0 microarray performed on RNA from L2 MECs of both genotypes (- control 
L2 / WAP-Cre+; Stop-150fl/fl L2), n=3. Genes within each category are sorted from 
greatest to smallest fold decrease based on the Mouse Transcriptome Array. All 
genes shown normally increase by two fold or greater at L2 compared to P14 based 






Figure 2.6. Mouse FASN is a direct target of miR-150-5p. (A,B) FASN protein 
was significantly decreased in L2 MECs from WAP-Cre+; Stop-150fl/fl mice compared 
to controls. Immunoblot analysis using antibodies against FASN, and α-tubulin as a 
loading control, 5 mice per genotype, quantification of immunoblot using Image 
Studio (bottom). Shown are mean±s.d., unpaired t-test (A). IHC for FASN (BD, 
610962) from mice at P14 and L2 (3 mice per indicated genotype) and negative 
control (no primary antibody), scale bar = 50μm (B). (C) The predicted miR-150-5p 
target site in position 378-384 of Fasn-3′ UTR is shown. 4T-1 cells were co-
transfected with scrambled negative control (NC) or miR-150-5p mimic (miR-150) 
together with pmirGLO Fasn-3′ UTR-WT or Fasn-3′ UTR-mut plasmids. Luciferase 
assay was performed. Shown are mean±s.d., n=3, unpaired t-test. Similar result was 
seen from 3 independent experiments. Luciferase reporter assays were performed 
by Hongwei Gao and Shang Chen. 
 






















bottom). This result indicates epithelial cell specific expression of exogenous miR-
150 coincided with MEC specific suppression of FASN. The ability of miR-150-5p to 
target a predicted site in the Fasn 3′ UTR was tested using a Fasn-3′ UTR-luciferase 
reporter assay (Fig. 2.6C). Co-transfection of miR-150 mimic resulted in a significant 
decrease in reporter activity (p=0.008) with the wt plasmid but not with the Fasn-3′ 
UTR-mut plasmid, indicating miR-150 is a bona fide target of mouse Fasn, acting on 
the 3′ UTR of Fasn containing the predicted binding site (Fig. 2.6C). While ACACA 
(a RNA22 predicted target of miR-150-5p) normally increased at the protein level 
between P14 and L2 (Fig. 2.7A top), epithelial expression of ACACA was 
significantly decreased (p=0.01) in L2 glands from WAP-Cre+; Stop-150fl/fl mice as 
shown by immunoblot analysis of MECs (~80% decrease) (Fig. 2.7B) and IHC (Fig. 
2.7A bottom). Although the transcript for Olah did not decrease with constitutive 
expression of miR-150 (Fig. 2.5), Olah is a predicted target of miR-150-5p 
(TargetScan) that is essential to MEC synthesis of medium chain fatty acids (MCFA) 
[133]. OLAH protein was suppressed with approximately 60% (p=0.006) in L2 MECs 
from WAP-Cre+; Stop-150fl/fl mice compared to control mice as quantified by 
immunoblot (Fig. 2.7C). Collectively, these results demonstrate that expression of 
multiple de novo fatty acid synthesis pathway components are suppressed by 
constitutive expression of miR-150. 
Constitutive expression of miR-150 results in reduced de novo fatty acid synthesis.  
To test the functional effects of the reduced levels of multiple proteins in the 
de novo fatty acid synthesis pathway, amounts of fatty acids were quantified from 




Figure 2.7. ACACA and OLAH, both involved in lipid synthesis, are also 
suppressed by constitutive expression of miR-150. ACACA and OLAH protein 
were significantly decreased in L2 MECs from WAP-Cre+; Stop-150fl/fl mice 
compared to controls (A) IHC for ACACA in mammary glands from mice at P14 and 
L2 (3 mice per indicated genotype) and negative control (no primary antibody), scale 
bar = 50μm. (B,C) Immunoblot analysis of MEC lysate using antibodies against 
ACACA, OLAH, and α-tubulin as a loading control, 5 mice per genotype, 
quantification of immunoblot was performed using Image Studio (bottom). Error bars 
represent standard deviation. Quantification excludes the third to last lane of the 























novo pathway in MECs, due to MEC specific expression of OLAH [133]. Quantitative 
lipid mass spectrometry revealed a significant reduction in MCFA, including 10:0 
(p=0.02), 12:0 (p=0.007), and 14:0 (p=0.01) (Fig. 2.8A) as well as their sum (inset, 
p=0.003) in MECs that constitutively express miR-150 compared to control MECs. 
Furthermore, 16:0, which can originate from either MEC de novo synthesis or be 
taken up from the serum, was also significantly decreased in MECs from mice with 
constitutive expression of miR-150 compared to controls (p=0.02). 18:0 can be 
produced in MECs by elongation of 16:0 and was also significantly reduced in MECs 
from mice with constitutive expression of miR-150 compared to control mice 
(p=0.003). Although the classes of monounsaturated fatty acids (MUFA) and 
polyunsaturated fatty acids (PUFA) were unchanged (Fig. 2.8B) in MECs from mice 
with constitutive expression of miR-150 compared to control mice, a significant 
increase in 22:4 n-6 (p=0.002) and a nearly significant increase in 22:5 n-3 
(p=0.052) were observed (Fig. 2.8C). Furthermore, fatty acids known to be taken up 
by MECs exclusively from dietary sources were not different (Fig. 2.8D). Collectively, 
quantitative GC-MS exposed the significant suppression of de novo synthesized 
fatty acids, further indicating that miR-150-5p profoundly modulates this enzymatic 
pathway in vivo. 
Discussion 
We identified a variety of miRNA in differentiated MECs, including miR-150-
5p, that decrease at the transition from pregnancy to lactation. These decreases 
occurred reciprocally with multiple mRNA increases in MECs upon secretory 
activation, suggesting that the decline in miRNA serves to relieve repression of  
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Figure 2.8. Constitutive expression of miR-150 results in reduced de novo fatty 
acid synthesis. Total lipids were extracted from L2 MECs from mice of both 
genotypes and quantified by GC-MS. (A) Synthesis of saturated fatty acids (SFA) 
were reduced overall in L2 MECs from WAP-Cre+; Stop-150fl/fl mice compared to 
controls. The sum of the de novo synthesized fatty acids (10:0-14:0, p=0.003) shown 
in the insert. (B and C) MUFA and PUFA fatty acid classes were unchanged by 
constitutive expression of miR-150 (B), but long chain-PUFA 22:4 n-6 was 
significantly increased (p=0.002) (C). (D) Dietary fatty acids in L2 MECs were 
unaffected by constitutive expression of miR-150. Shown are mean±s.d., n=5 for 
controls, n=3 for WAP-Cre+; Stop-150fl/fl, unpaired t-test, *p<0.05, **p<0.01. GC-MS 









mRNAs critical for effective lactation. To test this hypothesis we constitutively 
expressed miR-150-5p, the miRNA with the highest fold decrease between L2 
versus P14, to override its natural decline. My prediction was that transcripts 
targeted by miR-150-5p, which would normally be translated when this miRNA 
declines, would continue to be translationally inhibited with forced miR-150 
expression, resulting in impaired lactation. Indeed, we found that constitutive 
expression of miR-150-5p suppresses genes that code for proteins important for de 
novo fatty acid synthesis genes (FASN, ACACA, and OLAH) and cell survival 
(STAT5B) in mammary epithelium. My findings demonstrate that miR-150-5p directly 
targets the mouse Fasn and mouse Stat5b 3′ UTRs, suggesting regulatory control of 
two pathways critical for lactation. Cumulatively, when miR-150-5p is constitutively 
expressed, synthesis of de novo fatty acids is dramatically reduced affecting fatty 
acid content, which in concert with poor milk secretion, resulted in severe lactation 
deficit and high pup mortality.  
Consistent with miR-150-5p targeting Stat5b (Fig. 2.4D,E), constitutive 
expression of miR-150 results in a phenotype similar to that of Stat5b knockout mice 
[134]. Stat5b knockout mice had impaired milk production and a high incidence of 
perinatal pup death. Since STAT5 activity is important for survival of differentiated 
MECs [128], it is possible that targeted reduction of STAT5B protein and its activity 
by constitutive expression of miR-150 contributed to decreased MEC survival at 
lactation. Reduced alveolar density (Fig. 2.4A,C) and increased cleaved caspase 3 
in L2 mammary glands with constitutive expression of miR-150 (Fig. 2.4F) were 
consistent with this theory. Constitutive expression of miR-150 does not alter 
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signaling upstream of STAT5B since no differences were observed in activation of 
JAK2, a key mediator of PRLR signaling (Fig. A.5). Prlr mRNA was not suppressed 
by constitutive expression of miR-150 (Fig. 2.5). Suppression of STAT5B had no 
effect on the genes encoding β-casein and whey acidic protein (WAP) (Fig. A.5), 
likely because STAT5A is activated during secretory activation [135] and was not 
affected by constitutive expression of miR-150 (Fig. 2.4D). In contrast, suppression 
of both milk protein and lipogenic genes does occur when both STAT5A and 
STAT5B are repressed via inhibition of pituitary prolactin secretion [127, 136], or 
dominant negative prolactin mimetic [136].  
We found that constitutive expression of miR-150-5p suppressed lipid 
synthesis mRNAs at secretory activation (Fig. 2.5). It has been suggested that 
lipogenic gene induction is mediated in part by STAT5 activity [127]. Therefore, it is 
possible that down regulation of STAT5B and consequent STAT5 activity by miR-
150 contributes to suppression of lipogenic genes at the transcriptional level. 
However, my data strongly support an additional layer of miR-150-5p-mediated post-
transcriptional control of multiple enzymes essential for de novo fatty acid synthesis 
such as FASN, ACACA and OLAH (Figs 2.6,2.7).  
To reiterate, we confirm that FASN, ACACA and OLAH are affected at the 
protein level by constitutive expression of miR-150 expression. FASN synthesizes all 
de novo fatty acids [131], ACACA is the primary rate limiting enzyme in the de novo 
pathway responsible for supplying malonyl-CoA substrate to FASN [130], and OLAH 
releases the growing fatty acid chain specifically for MCFA [133]. Interestingly, 
numerous other predicted targets in this same pathway were suppressed two-fold or 
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more by constitutive expression of miR-150 (Fig. 2.5) including Thrsp, required for 
MCFA synthesis in MECs [125], Acly, responsible for synthesis of the substrate 
acetyl-CoA used for de novo fatty acid synthesis [129], and Slc25a1, which shuttles 
substrate into the de novo fatty acid synthesis pathway [132]. These targets, like 
FASN, may be suppressed even more strongly at the protein level. Likely due to 
suppression of multiple key components of this pathway, MECs from WAP-Cre+; 
Stop-150fl/fl mice had a profound deficit in saturated fatty acids (Fig. 2.8A), with 
notably less de novo fatty acid synthesized MCFA per mole of TAG, including 10:0, 
12:0, and 14:0.  
Constitutive expression of miR-150 in MECs bears similarity to the mammary 
gland specific Fasn knockout (Fasn KO), which had a lactation defect characterized 
by decreased pup weight, increased pup mortality, and milk containing significantly 
less 14:0, 16:0, 18:0, and overall fatty acids compared to controls [10]. However, 
constitutive expression of miR-150 additionally affected the MCFA 10:0 and 12:0 
(Fig. 2.8A) and demonstrated a more dramatic effect on pup mortality. This broader 
reduction in MCFA, can be attributed to suppression of the aforementioned 
additional key enzymes involved in de novo fatty acid synthesis. Furthermore, 
reduction in 18:0 (Fig. 2.8A) is also consistent with the observed decrease in its 
synthetic precursor, 16:0 (Fig 2.8A), plus decreases in mRNA for fatty acid 
elongases such as Elovl 6 (Fig. 2.5) that catalyze the synthesis of 18:0 from 16:0 
[137]. Despite decreased 18:0 substrate levels (Fig 2.8A) and the observed 
reductions of Scd1 and Scd2 mRNA (Fig. 2.5), their product, 18:1 n-9, remained 
unaffected likely due to the high quantity of 18:1 n-9 in our rodent diet. Thus, 
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constitutive expression of miR-150 results in broader defects of milk fat composition 
than the Fasn KO, affecting both MCFA and long chain fatty acids.  
It is likely that functional redundancies evolved such that multiple miRNAs, 
including miR-150, control lactation. For example, at least six other miRNAs that 
decline precipitously at secretory activation are predicted to target Fasn, including 
miR-342-3p, miR-361-5p, miR-425-5p, miR-17-3p, miR-15b-5p and miR-532-5p 
(Table 2.1). Functional overlap is also evident in miRNAs predicted to target milk 
protein genes. For example, lactotransferrin (Ltf), is predicted to be targeted by six 
miRNAs significantly downregulated just prior to lactation, only two of which are part 
of the miR-17/92 cluster (Table A.1). Likewise, only one of the six miRNAs listed 
above that decline precipitously at secretory activation and are predicted to target 
Fasn is part of the miR-17/92 cluster (Table 2.1). Therefore, it is not surprising that 
knockout of the miR-17/92 cluster did not affect mammary development [138]. Due 
to the compensatory mechanisms that likely evolved for a process as critical to 
mammalian survival as lactation, forced expression to override the natural decrease 
in a miRNA may be a more effective method to evaluate the contribution of a specific 
miRNA to mammary gland development than a knockout approach.  
Herein we describe the effects of preventing the natural decline of a miRNA, 
miR-150, between late pregnancy and lactation. My data support the hypothesis that 
a precipitous decline in a program of miRNAs, such as miR-150, provides a level of 
control over translation of specific proteins for the survival and function of 




SUBTYPE SPECIFIC FUNCTIONS OF MICRORNA-150 IN BREAST CANCER 
Background 
As reviewed in Chapter I, dysregulated miRNAs can contribute to the cancer 
phenotype. Expression of particular miRNAs may be lost or overexpressed, allowing 
for aberrant gene expression, thereby affecting some oncogenes or tumor 
suppressors. Interestingly, a study of differentially expressed miRNAs involved in 
eight different models of mouse mammary carcinoma, miR-150-5p was found to be 
one of only five miRNAs consistently lower in tumor compared to normal mammary 
epithelial cells [139]. The mouse models used represent a variety of alterations 
observed in human breast cancer and include the following: MMTV-H-Ras, -
Her2/neu, -c-Myc, -PymT, -Wnt1 and C3(1)/SV40 T/t-antigen transgenic mice, 
BRCA1(fl/fl);p53(+/-);MMTV-cre knock-out mice and the p53(fl/fl);MMTV-cre 
transplant model. This decrease in expression of miR-150-5p in mouse mammary 
carcinoma suggests a tumor suppressive role in human breast cancer. 
Several other solid tumors have categorized miR-150-5p as a tumor 
suppressor, including pancreatic cancer where miR-150-5p targets mucin 4 (MUC4) 
[140], esophageal cancer where it targets ZEB1 [141], colorectal cancer were it has 
been indicated as a potential biomarker for prognosis [142], and liver cancer where it 
targets MYB [143]. Interesting, all three validated oncogenic targets in these solid 
tumors also have relevance in breast cancer. ZEB1 and MYB in particular are 
subtype specific genes with ZEB1 primarily expressed in TNBC [144] and MYB 
primarily expressed in ER+ breast cancer [145]. The reason breast cancer cells 
53 
 
exhibit this dichotomy in expressing either ZEB1 or MYB might be in the fact that 
MYB is transcriptionally downregulated by ZEB1 [146]. When ZEB1 is 
inappropriately expressed in TNBC it initiates an EMT because ZEB1 represses E-
cadherin and other genes involved in polarity [147]. ZEB1 induced EMT confers 
invasive capabilities that promote metastatic progression [86, 148, 149]. Repression 
of E-cadherin by ZEB1 can in turn release β-catenin, which can activate genes that 
stimulate cell proliferation, such as cyclin D1 [150, 151] and v-myc avian 
myelocytomatosis viral oncogene homolog (MYC) [152]. For ER+ breast cancers, 
MYB is a confirmed target for miR-150-5p [153] that is a frequently overexpressed 
transcription factor [154] and was found to be essential for proliferation of breast 
cancer cell lines where it suppresses differentiation and apoptosis [155, 156]. MYB 
appears to be required for HER2-driven tumorigenesis [157]. It is also required for 
ongoing proliferation of MCF7 cells [155, 156] and ZR-75-1 xenograft tumors [157]. 
The downstream targets of MYB are not as well identified as ZEB1 partially due to 
alternatively spliced transcripts and post translational modifications, which lead to a 
variety of targets, depending on the cell context [158]. One possible explanation for 
MYB’s role in proliferation is that it can control the cell cycle through regulation of 
Cyclin B1, Cyclin D1, cyclin-dependent kinase 4 (CDK4), and cyclin-dependent 
kinase 6 (CDK6) [159-161]. If miR-150-5p also functions as a tumor suppressor in 
breast cancer, we hypothesized that it would allow expression of protumorigenic 
genes such as ZEB1 and MYB. 
In the present study, we investigated the functions of miR-150-5p in human 
breast cancer. My findings demonstrate a loss of miR-150-5p expression in breast 
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cancer regardless of ER status. Furthermore, miR-150-5p restoration to breast 
cancer cell lines result in growth suppression, possibly due in part to the repression 
of targets ZEB1 protein in TNBC and MYB protein in ER+ breast cancer, but I also 
identified additional targets by performing gene expression profiling of breast cancer 
cell lines with or without expression of exogenous miR-150-5p. 
Materials and Methods 
Human Tissues 
ER+ Breast Cancer:  Postmenopausal women (n=10) with newly diagnosed 
ER+ breast cancer, grade 1-2, stage II/III were included in this study. The protocol 
(01-627) was approved by the Colorado Multiple Institutional Review Board 
(COMIRB) and informed consent was provided by all patients. TNBC: Patients 
(n=10) ranged in age from 36-72 years old with a mean age of 52.11 ± 4.7 years. All 
TNBC tumors were grade 3, ER-, PR- and not HER2 amplified (COMIRB protocol 
04-0066). Tumor specimens were formalin-fixed and paraffin-embedded (FFPE) by 
the University of Colorado Hospital. 
miRNA ISH  
Sections of tumor were analyzed by ISH as described in [120]. A hybridization 
temperature of 53°C and miRCURY LNA microRNA Detection Probes pre-labeled 
with double digoxigenin and complementary to mature miR-150-5p 
(CACTGGTACAAGGGTTGGGAGA) (Exiqon) were used. 
Microscopy 
Representative images of tumor and adjacent normal were taken from ISH 
slides using an Olympus BX40 microscope with a SPOT Insight Mosaic 4.2 camera 
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and software (Diagnostic Instruments, Inc.). 
Cell culture 
HMLE and MCF-10A, which are ER-, PR-, not HER2 amplified, non-
transformed human MEC cell lines, were grown in Dulbecco’s Modified Eagle 
Medium / Ham’s F-12 nutrient mixture (DMEM/F12) supplemented with 5% fetal 
bovine serum (FBS), 5 µg/mL insulin, 1 µg/mL hydrocortisone, 3 µg/mL prolactin, 
and 5 ng/mL epidermal growth factor (EGF). MCF-7 and ZR-75-1, which are ER+, 
PR+, and not HER2 amplified, were grown in minimum essential medium (MEM) 
supplemented with 5% FBS, and insulin and Roswell Park Memorial Institute 
medium (RPMI-1640) supplemented with 10% FBS, respectively. BT-549 and MDA-
MB-231, which are ER-, PR-, and not HER2 amplified, were grown in RPMI-1640 
supplemented with 10% FBS and MEM supplemented with 5% FBS, non-essential 
amino acids (NEAA), HEPES, and insulin, respectively. Inducible cell lines were 
grown in the same conditions but with tetracycline-free FBS (Clontech, Mountain 
View, CA, USA). All cells were maintained at 37°C and 5% carbon dioxide, and 
fingerprinted for authenticity using the Identifiler DNA profiling kit (ABI, Grand Island, 
NY, USA) at the University of Colorado Cancer Center Sequencing Core Facility. 
RNA Isolation 
Total RNA was isolated from breast cancer cells using Trizol Reagent 
(Thermo Fisher Scientific). RNA concentration and purity were assessed in Applied 




cDNA was synthesized using Taqman MicroRNA Reverse Transcription kit 
(Thermo Fisher Scientific) and miRNA-specific RT primers as per manufacturer’s 
recommendations. PCR for each miRNA was performed using specific Taqman 
MicroRNA probe and TaqMan Universal PCR Master Mix No AmpErase UNG (2×) 
(Thermo Fisher Scientific). Quantification of miRNA was determined by the Ct 
method. To calculate 2-ΔΔCt, the Ct values for RNAU6 were subtracted from Ct values 
of the miRNA to achieve the ΔCt value. The ΔCt of a control sample was then 
subtracted from each ΔCt to achieve the relative miRNA levels (ΔΔCt). Fold change 
is calculated (2-ΔΔCt). 
Transduction 
Cell lines with stable expression of miR-150 precursor were generated using 
lentiviral transduction with a pCDH-CMV-MCS-EF1-copGFP cDNA cloning and 
expression vector (System Biosciences Inc., Palo Alto, CA, USA). The pMIR-cGFP-
Zeo pre-miRNA control vector containing a scrambled (SCR) hairpin sequence was 
used to create the matching control cells. Selection was performed by flow sorting 
for green fluorescent protein (GFP) positive cells by the University of Colorado 
Cancer Center Flow Cytometry Shared Resource.  
Cells were also transduced with a doxycycline (Dox) inducible lentiviral vector 
(pTRIPz) (Dharmacon, Inc., Lafayette, CO, USA) encoding miR-150 or an empty 
vector (EV) and selected using puromycin. The pooled population of transduced 
MCF-7 cells and a clone of inducible ZR-75-1 cells, demonstrating robust expression 
of miR-150-5p with less background than the pooled population, was used in all 
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subsequent experiments. miR-150-5p expression was induced with 1 μg/mL Dox for 
72 hours before harvesting for RNA and protein. 
Transfection 
Mature miR-150-5p (miRNA mimic) or non-specific negative control (NC) 
(Ambion) at a concentration of 50 nM were incubated with Lipofectamine RNAiMAX 
(Invitrogen, Carlsbad, CA, USA) in culture medium per the manufacturer's 
instructions before addition to cells. Mock transfection using just lipofectamine 
without added RNA was also used as a negative control along with parental cell 
lines. Cells were incubated at 37°C for 24 hrs before replacement of medium. 
Transfected cells were then harvested for RNA and protein at 72 hours, with the 
exception of ZR-75-1. Protein was isolated from ZR-75-1 cells at 24 hours and the 
microarray data was done on RNA isolated from ZR-75-1 cells at 48 hours. Cells 
were transfected for 24 hours before plating for crystal violet growth assays. 
2D growth assays 
For endpoint crystal violet growth assays, cells were plated at an optimal 
density (1,500-12,000 cells per well) for an optimal length of time (6-10 days) 
depending on the cell line and whether it was a 12 or 6 well plate. Cells were then 
fixed in 10% formalin, rinsed in PBS, and stained with 5% crystal violet. After photos 
of the plates were taken, the crystal violet was dissolved in 10% acetic acid and was 
measured at an absorbance of 540λ (A540) as a measurement of cell growth. 
Cell growth was also measured using the IncuCyte ZOOM kinetic cell imaging 
system (Essen BioSciences, Ann Arbor, MI, USA) by plating cells in a 96 well plate 
at an optimal density (500-2,000 cells per well) depending on the cell line. Cells were 
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induced with 1 μg/mL Dox 24 hours after plating, and IncuCyte images were taken 
starting 0-4 hours after induction. 
Immunoblot 
Protein resolved by polyacrylamide gel electrophoresis (40 µg) was 
transferred to Immobilon-FL membranes (Millipore Continental Water Systems). The 
membranes were blocked with 5% milk in PBS, probed with primary antibodies 
overnight at 4°C, washed and incubated with appropriate Alexa Fluor secondary 
antibody (Thermo Fisher Scientific). The primary antibodies used were anti-ZEB1 
(generous gift of Dr. Doug Darling, University of Louisville, Louisville, KY, USA), anti-
MYB (Abcam, 45150), and anti-α-tubulin loading control (Sigma, T5168). Protein 
from each sample was detected by immunoblot using Odyssey infrared imager (LI-
COR Biosciences). 
Microarray hybridization 
Triplicate RNA samples from 72 hour transfections of BT-549 cells and 48 
hour transfections of ZR-75-1 cells were analyzed by microarray. One µg of total 
RNA from each sample was labelled with FlashTag Biotin RNA Labeling kit 
(Genisphere) and hybridized onto Human Gene 2.0 ST (Affymetrix) according to the 
manufacturer’s recommendations and performed in the University of Colorado 
Cancer Center Microarray Core Facility. The raw data for both arrays are available 
at http://www.ncbi.nlm.nih.gov/geo under series record GSE87590. 
Microarray data analysis 
The Significance Analysis of Microarrays (SAM) software was applied for 
microarray data analysis [162]. Comparisons were made between mimic and mock 
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transfections as well as mimic and NC transfections. The differently expressed 
genes between mimic transfected cells and each of the two negative controls (mock 
and NC transfected) were identified with a FDR < 0.15. The FDR values were 
calculated using the permutation-based analysis algorithm of SAM [162]. Targets of  
hsa-miR-150-5p were bioinformatically predicted using TargetScan Human v7.0 [61]. 
Microarray data comparing mimic transfection to the controls was also analyzed with 
Gene Set Enrichment Analysis (GSEA) using a curated gene set (c2.v1.symbols) 
from the Molecular Signatures Database and 500 gene set permutations. 
Results 
miR-150-5p is lower in tumor compared to adjacent normal in human breast cancer 
regardless of subtype. 
To determine if low miR-150-5p in tumor versus normal was as true in 
humans as it was in 8 mouse models of mammary gland carcinoma [139], 10 FFPE 
specimens each from ER+ and TNBC tumors were analyzed by ISH. Only 7 of the 
ER+ specimens and 9 of the TNBC specimens had matching adjacent normal (non-
involved) tissue contained in the same section as tumor. Of those, the majority (5 
ER+ and 6 TNBC) show a pattern of expression where miR-150 is lower in tumor 
compared to adjacent normal (Fig. 3.1A), while the remaining samples showed a 
similar signal intensity between tumor and adjacent normal. A lower power image of 
one example demonstrates what is meant by adjacent normal (Fig 3.1B). In addition, 






Figure 3.1. miR-150-5p is lower in tumor compared to adjacent normal in 
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Figure 3.1. miR-150-5p is lower in tumor compared to adjacent normal in 
human breast cancer regardless of subtype. ISH analysis for mature miR-150-5p 
in human breast cancer FFPE clinical specimens from 6 representative patients (3 
per subtype). (A) Tumor and adjacent normal tissue from the same section are 
shown. Positive control (RNAU6 probe) and negative control (no probe), scale bar = 
50μm. (B) Representative ISH from patient 4 at low power magnification, scale bar = 




miR-150-5p is lower in breast cancer cell lines compared to the normal expression in 
mouse MECs. 
The low expression of miR-150-5p found in human breast cancer tumors may 
also apply to breast cancer cell lines, thus providing an in vitro model to investigate 
the role of miR-150-5p in breast cancer. Relative miR-150-5p expression assessed 
by qRT-PCR was compared between “normal” non-transformed human MEC cell 
lines (HMLE and MCF-10A), ER+ breast cancer cell lines (MCF-7 and ZR-75-1), and 
TNBC cell lines (BT-549 and MDA-MB-231) (Fig. 3.2A). On average, ER+ breast 
cancer cell lines have about 4 fold higher endogenous expression of mature miR-
150-5p compared to TNBC cell lines, but the “normal” cell lines did not contain a 
comparatively higher expression of miR-150-5p as was expected. This may be due 
to the “normal” cell lines being immortal and not true representations of normal 
human MECs. It is known that these cells are not well-differentiated and have lost 
expression of ER and PR [163, 164]. 
For a better representation of the expression level of miR-150-5p found in 
never-cultured MECs, RNA isolated from a breast cancer cell line was additionally 
compared to RNA isolated from mouse MECs at P14 and L2 (Fig. 3.2B). These were 
the same mouse MECs used for Fig 2.1B. MDA-MB-231 cells were transduced with 
either lentiviral vector encoding a pri-miRNA-150 or SCR control to serve as 
examples of the endogenous level found in breast cancer (SCR) and the level post 
restoration. Although restoration of miR-150-5p to the MDA-MB-231 cell line was 
upwards of 10,000 fold, this magnitude of restoration was necessary to bring the 




Figure 3.2. miR-150-5p is lower in breast cancer cell lines compared to the 
normal expression in mouse MECs. TaqMan qRT-PCR was used to quantify miR-
150-5p expression normalized to RNAU6. (A) Endogenous levels in “normal” human 
MEC lines, ER+ breast cancer cell lines, and TNBC cell lines (2 cell lines per 
category). (B) Relative miR-150-5p expression in breast cancer cell line MDA-MB-
231 transduced with lentiviral vectors containing either miR-150 precursor or SCR 
control compared to expression found in normal mouse MECs at P14 or L2. Error 
bars for transduced MDA-MB-231 represent standard deviation, n=3. PCR was 






(Fig. 3.2B). It is within this range found in normal MECs where a threshold exists for 
miR-150 to achieve regulatory control over many genes associated with mammary 
gland development (Chapter II), some of which may be relevant in breast cancer. 
Restoration of miR-150-5p decreases breast cancer cell growth in 2D culture. 
Enhanced cell growth is a major characteristic of cancer. To determine if the 
low expression of miR-150 in breast cancer cell lines contributes to this 
characteristic of cancer, miR-150 was restored to breast cancer cell lines 
representing ER+ and TNBC subtypes using three different techniques.  
Restoration by transduction with lentiviral vector containing a miRNA-150 
precursor, as was done for the MDA-MB-231 cells described for Fig. 3.2B, was also 
done for MCF-7 and BT-549 cells. Degree of miR-150-5p restoration for these 
transduced cells was assessed by qRT-PCR for the mature miR-150-5p (Fig 3.3A 
left). Even though restoration of miR-150-5p by stable transduction with miR-150 
precursor only reached about 1,000 fold higher than SCR controls in the MCF-7 
cells, and 200 fold higher than SCR controls in the BT-549 cells, this was enough to 
significantly reduce growth by ~60% (p=0.0006) in the MCF-7 cells and ~30% 
(p=0.04) in the BT-549 cells compared to SCR controls (Fig. 3.3B left). 
Transient transfection of mature miR-150-5p mimic was used to restore miR-
150-5p levels in MDA-MB-231 and BT-549 cells. The mature mimic was utilized 
because our lab has published that TNBC has low levels of dicer, rendering it 
difficult to make mature miRNA from the precursor [120, 165]. Restoration of miR-
150-5p to both cell lines using mimic resulted in about 10,000 fold greater miR-150-
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Figure 3.3. Restoration of miR-150-5p decreases breast cancer cell growth in 
2D culture. (A) TaqMan qRT-PCR quantification of miR-150-5p restoration following 
stable transduction with lentivirus containing miR-150 precursor compared to SCR 
control or by 72 hour transient transfection with mature miR-150 mimic compared to 
the parental cell line, mock transfection, or NC. Shown are mean±s.d., normalized to 
RNAU6, n=3, unpaired t-test. (B) Crystal violet growth assays following miR-150 
restoration via lentiviral vector or mimic compared to their respective controls. 
Shown on top are images of 2D growth taken at endpoint and optical density 
quantifications shown below with mean±s.d., n=3, unpaired t-test. (C) TaqMan qRT-
PCR quantification of miR-150 normalized to RNAU6 in Dox inducible cell lines 
compared to the parental cell line or EV controls. Shown are mean±s.d., n=3, 
unpaired t-test. (D) Time course growth curves for Dox inducible cell lines compared 
to their respective controls. Shown are mean±s.d., n=6 for MCF-7, n=20 for ZR-75-1, 




72 hour transfections (Fig. 3.3A right). This significantly reduced cell growth in MDA-
MB-231 and BT-549 cells by ~30% (p<0.0001 and p=0.01, respectively) compared 
to NC (Fig. 3.3B right). 
Restoration of miR-150-5p was also accomplished with Dox inducible MCF-7 
and ZR-75-1 cells. Three days of induction resulted in almost 100,000 fold higher 
expression of miR-150-5p in induced mir-150 cells compared to parental and EV 
controls as assessed by qRT-PCR (Fig. 3.3C). While still significantly lower than 
their induced counterparts, untreated miR-150 cells displayed leaky expression of 
miR-150-5p of up to 1,000 fold. Despite this, real-time growth assays measuring fold 
change of percent phase confluence show a significant reduction in growth for 
induced miR-150 cells compared to untreated miR-150 cells and EV controls. 
Induced MCF-7 cells containing the miR-150 vector showed a reduced growth by 
~30% (p=0.001) compared to untreated miR-150 cells and EV controls at the last 
timepoint measured (Fig. 3.3D left). Induced ZR-75-1 cells containing the miR-150 
vector showed a reduced growth by ~50% compared to EV controls at the last 
timepoint measured, but growth was still significantly reduced by ~30% (p<0.0001) 
compared to untreated miR-150 cells (Fig. 3.3D right). 
Restoration of miR-150-5p suppressed ZEB1 in two TNBC cell lines. 
ZEB1 is a known target of miR-150-5p in esophageal cancer [141]. ZEB1 can 
contribute to cancer cell growth [166], and it is primarily expressed in TNBC [144], 
ZEB1 could be a relevant target of miR-150 in restored TNBC cell lines. To test 
whether miR-150-5p targets and represses ZEB1 in TNBC, miR-150-5p was 
restored to TNBC cell lines MDA-MB-231 and BT-549 cells by transient transfection 
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with mature miR-150-5p mimic for 72 hours (Fig. 3.3A right). Immunoblot for ZEB1 
revealed a significant reduction by ~50% (p<0.0001) in MDA-MB-231 cells and 
~60% (p=0.03) in BT-549 cells compared to parental, mock and NC controls (Fig. 
3.4). 
Restoration of miR-150-5p reverses EMT associated pathways and other genes 
identified as putative targets in the BT-549 breast cancer cell line. 
To identify other relevant targets of miR-150-5p in TNBC, global mRNA 
profiling was performed on BT-549 cells that were transfected with miR-150 mimic 
for 72 hours. Analysis of the gene expression profiling data with SAM identified 600 
upregulated genes and 1634 downregulated genes between mimic versus NC 
transfected cells. To narrow the list down and remove any off-target effects of the 
NC, entities not also significantly different between mimic versus mock were 
removed. This resulted in 24 downregulated genes and 13 upregulated genes that 
were common to the comparisons of mimic versus NC and mimic versus mock (Fig. 
3.5A). Of these, 19 are predicted to be targeted by miR-150-5p at the 3′ UTR 
(TargetScan) (Fig. 3.5A) including the only validated target in the list, ZEB1. 
Consistent with the immunoblot analysis, downregulation of ZEB1 transcript 
suggests that direct targeting by miR-150-5p leads to ZEB1 mRNA degradation by 
deadenylation or cleavage. 
ZEB1 initiates an EMT when it is expressed in breast cancer cell lines since it 
is a direct transcriptional repressor of the epithelial marker E-cadherin [147]. Since 
miR-150-5p targets and decreases ZEB1, I hypothesized that restoration of miR-




Figure 3.4. Restoration of miR-150-5p suppressed ZEB1 in two TNBC cell lines. 
Immunoblot analysis of 72 hour transfected TNBC cell lines using antibodies against 
indicated proteins and α-tubulin as a loading control with quantification shown below. 
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Figure 3.5. Restoration of miR-150-5p reverses EMT associated pathways and 
other genes identified as putative targets in the BT-549 breast cancer cell line. 
(A) Affymetrix GeneChip Human Gene 2.0 ST array heatmap depicting normalized 
signal values of significant differentially expressed genes between 72 hour miR-150 
mimic transfected BT-549 cells compared to mock and NC controls (n=3). Asterisks 
indicate predicted targets of miR-150-5p based on TargetScan. (B) GSEA generated 








of the gene expression profiling data with GSEA’s algorithm identified enrichment of 
curated gene lists with nominal p-values below 0.06 including EMT Down (p=0.04), 
Cell Adhesion (p<0.001), and Cell Adhesion Receptor Activity (p=0.05), suggesting 
at least a partial reversal of EMT upon restoration of miR-150-5p (Fig. 3.5B). 
Restoration of miR-150-5p suppresses MYB in two ER+ breast cancer cell lines. 
MYB is a known target of miR-150-5p in B-cells [106]. MYB has been 
reported to contribute to breast cancer cell growth [155, 156], and it is primarily 
expressed in ER+ breast cancer [145, 169]. To test whether miR-150-5p targets and 
represses MYB in ER+ breast cancer, miR-150-5p was restored to ER+ breast 
cancer cell lines MCF-7 and ZR-75-1 cells by transient transfection with mature miR-
150-5p mimic (Fig. 3.6A). Restoration of miR-150-5p to MCF-7 cells using mimic 
resulted in about 60,000 fold greater miR-150-5p expression than parental, mock, 
and NC controls as assessed by qRT-PCR after 72 hour transfections (Fig. 3.6A 
left). Restoration of miR-150-5p to ZR-75-1 cells using mimic resulted in about 2,000 
fold greater miR-150-5p expression than parental, mock, and NC controls as 
assessed by qRT-PCR after 24 hour transfections (Fig. 3.6A right). Immunoblot for 
MYB revealed a significant reduction by ~100% (p=0.0004) in MCF-7 cells (72 hour 
transfection) and ~80% (p=0.0004) in ZR-75-1 cells (24 hour transfection) compared 
to parental, mock and NC controls (Fig. 3.6B). Dox inducible cell lines were also 
made to restore miR-150-5p to the ER+ cell lines. Restoration of miR-150-5p in 
inducible cell lines after a 72 hour induction (Fig. 3.3C) also shows a significant 
reduction of MYB by ~90% in both MCF-7 cells (p=0.009) and ZR-75-1 cells 
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Figure 3.6. Restoration of miR-150-5p suppresses MYB in two ER+ breast 
cancer cell lines. Suppression of MYB in MCF-7 and ZR-75-1 ER+ cell lines is 
shown after restoration with mature miR-150 mimic and inducible miR-150 
precursor. (A) TaqMan qRT-PCR quantification of miR-150-5p restoration following 
72 hour transfection of MCF-7 cells and 24 hour transient transfection of ZR-75-1 
cells with mature miR-150 mimic compared to the parental cell line, mock 
transfection, or NC. Shown are mean±s.d., normalized to RNAU6, n=3, unpaired t-
test. (B) Immunoblot analysis of 72 hour transfection of MCF-7 cells and 24 hour 
transient transfection of ZR-75-1 cells using antibodies against indicated proteins 
and α-tubulin as a loading control with quantification shown below. Shown are 
mean±s.d., n=3, unpaired t-test. (C) Immunoblot analysis of 72 hour induced ER+ 
breast cancer cell lines using antibodies against indicated proteins and α-tubulin as 





immunoblot (Fig. 3.6C). 
Restoration of miR-150-5p suppresses Fatty Acid Synthesis pathway and other 
genes identified as putative targets in the ZR-75-1 breast cancer cell line. 
To identify other relevant targets of miR-150-5p in ER+ breast cancer, global 
mRNA profiling was performed on ZR-75-1 cells that were transfected with miR-150 
mimic for 48 hours. Analysis of the gene expression profiling data with SAM 
identified 6 upregulated and 114 downregulated genes between mimic and NC 
transfected cells (Fig. 3.7A). Only disintegrin and metalloproteinase domain 19 
(ADAM19), solute carrier family 7 member 11 (SLC7A11) and sestrin 3 (SESN3) 
were common in the mimic versus mock comparison. MYB transcript was not 
downregulated by miR-150 restoration, although the protein is, further suggesting 
miR-150-5p targets MYB through translational repression. While there are no 
validated targets in the list of differentially expressed genes between mimic and NC, 
44 are predicted to be targeted by miR-150-5p at the 3′ UTR (TargetScan) (Fig 
3.7A). There was very little overlap in relevant targets between both gene profiling 
experiments performed on the ER+ cell line ZR-75-1 and the TNBC cell line BT-549, 
with only 6 genes similarly altered: carboxypeptidase D (CPD), FGFR1OP N-
terminal like (FOPNL), procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 (PLOD2), 
dolichyl-diphosphooligosaccharide-protein glycosyltransferase non-catalytic subunit 
(DDOST), glutathione reductase (GSR), cluster of differentiation 109 (CD109). 
GSEA was also performed on the gene expression profiling data from miR-150-5p 
restored ZR-75-1 cells. Most notably, Fatty Acid Synthesis was one of the top 
ranked downregulated pathways with a nominal p-value of 0.009 (Fig. 3.7B). Fatty 
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Figure 3.7. Restoration of miR-150-5p suppresses Fatty Acid Synthesis 







































































































































Figure 3.7. Restoration of miR-150-5p suppresses Fatty Acid Synthesis 
pathway and other genes identified as putative targets in the ZR-75-1 breast 
cancer cell line. (A) Affymetrix GeneChip Human Gene 2.0 ST array heatmap 
depicting normalized signal values of significant differentially expressed genes 
between 48 hour miR-150 mimic transfected ZR-75-1 cells compared to NC control 
(n=3). Relative levels of gene expression in the Mock transfection control are also 
shown. Asterisks indicate predicted targets of miR-150-5p based on TargetScan. 
Bottom half of the heatmap is continued on the right. (B) GSEA generated 




acid synthesis is required in cancer cells for membrane proliferation and the 
generation of signaling molecules (as reviewed in [170]). This is consistent with 
evidence shown in Chapter II that miR-150-5p regulates fatty acid synthesis in the 
context of normal MECs, which are likely to share similar targets with the more 
differentiated ER+ cancer cells than the less-well differentiated TNBC cells. For the 
Fatty Acid Synthesis pathway, this common gene is protein kinase, AMP-activated, 
alpha 2 catalytic subunit (PRKAA2). PRKAA2 is suppressed by constitutive 
expression of miR-150-5p in the mouse model described in Chapter II (fold 
change=2.2, p=0.03) and also suppressed by miR-150-5p restored to ZR-75-1 cells 
(Fig. 3.7A). 
Discussion 
In summary, my data suggests a propensity for miR-150-5p loss in breast 
cancer clinical specimens and cell lines, regardless of ER status (Fig. 3.1, 3.2). This 
loss contributes to increased cell growth since 2D growth is suppressed upon 
restoration of miR-150-5p in cell lines representing two of the main breast cancer 
subtypes (ER+ and TNBC) (Fig. 3.3). This suppression may be due in part to the 
decrease of known miR-150-5p targets ZEB1 in TNBC cell lines (Fig. 3.4) and MYB 
in ER+ breast cancer cell lines (Fig. 3.6).  Other putative targets that are suppressed 
at the transcript level have been identified, and many of them are also subtype 
specific (Figs. 3.5A,3.7A). The genes affected by miR-150-5p restoration in BT-549 
cells strongly suggest miR-150-5p is capable of partially reversing EMT in TNBC 
(Fig. 3.5B), while analysis of affected genes in restored ZR-75-1 cells suggests that 




Although MYB and ZEB1 are either known or have potential to contribute to 
cell growth in breast cancer [155, 156, 166] they are not likely to be the sole targets 
responsible for the decrease in cell growth observed upon restoration of miR-150-
5p. Gene expression profiling of one cell line from each breast cancer subtype 
revealed putative targets that have known involvement in proliferation. Therefore, 
since they are suppressed by miR-150-5p, they could also be responsible in part for 
the reduced growth. For the BT-549 cells, this includes predicted targets tenascin C 
(TNC) [171], myocyte enhancer factor 2 (MEF2D) [172], beta 1,4-
galactosyltransferase 1 (B4GALT1) [173], and CD109 [174] (Fig. 3.5A). While in ZR-
75-1 cells, this includes predicted targets CD109 [174], ras-related protein Rab-31 
(RAB31) [175], purinegic receptor P2Y2 (P2RY2) [176], paternally expressed 10 
(PEG10) [177], PDZ and LIM domain 1 (PDLIM1) [178], and polypeptide N-
acetylgalactosaminyltransferase 6 (GALNT6) [179] (Fig. 3.7A). Decreased 
expression of non-predicted targets as well as secondary targets could also 
contribute to growth suppression. For BT-549 cells, these include mucin 1 (MUC1) 
[180] and snail family zinc finger 2 (SNAI2) [181] (Fig. 3.5A). While in ZR-75-1 cells, 
this includes metallothionein 2A (MT2A) [182], anoctamin 1 (ANO1) [179], inhibitor of 
DNA binding 1 (ID1) [183], related RAS viral (R-Ras) oncogene homolog (RRAS) 
[184], transient receptor potential cation channel subfamily V member 6 (TRPV6) 
[185], ADAM metallopeptidase with thrombospondin type 1 motif 1 (ADAMTS1) 
[186], tryptophan 2,3-dioxygenase (TDO2) [187], and inhibitor of DNA binding 3, 
HLH protein (ID3) [188] (Figs. 3.7A). 
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My data support a tumor suppressive role for miR-150. This is based on low 
expression levels of miR-150-5p in tumor compared to normal (Figs. 3.1,3.2B), lower 
average levels in the more aggressive TNBC subtype compared to ER+ breast 
cancer (Figs. 3.1,3.2A), reduced growth upon restoration of miR-150-5p to 
physiologically relevant levels in breast cancer cell lines (Fig. 3.3), and an inverse 
correlation to expression of tumor promoting genes like ZEB1 (Fig. 3.4) and MYB 
(Fig 3.6). Like miR-205 in breast cancer [75], there are conflicting reports over the 
function of miR-150-5p in breast cancer. A plethora of studies have utilized global 
miRNA expression profiling to identify dysregulated miRNAs in breast cancer [103, 
189-194]. Perhaps since these studies utilize whole tumor tissue, and contamination 
by miR-150-5p expressing lymphocytes [105] may mask any difference in 
expression, miR-150-5p has yet to be identified as a biomarker for diagnosis, 
prognosis, or prediction of therapeutic outcome. Huang et. al. describes miR-150-5p 
as an oncogene in breast cancer, with evidence in almost complete contradiction to 
my own data [195]. They reported higher levels of miR-150-5p in human breast 
cancer tumors compared to non-involved normal mammary tissue as determined by 
ISH and qRT-PCR. Since both of our cohorts were not large, it is possible that the 
differences in our ISH data are a result of differences between the populations of 
women included in our cohorts much like the reasoning behind TNBC being more 
commonly diagnosed in African American women [33-38]. Huang et. al. also altered 
miR-150-5p expression in breast cancer cell lines by overexpression with mimic or 
inhibition with antagamirs, small complementary strands or RNA designed to block 
function of oncogenic miRNAs. This provided further evidence of an oncogenic role 
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based on cell growth and apoptosis assays along with the inversely expressed tumor 
suppressor target, purinergic receptor (P2RX7) [195]. They did not report a fold 
change or provide a figure on their qRT-PCR data to show how much higher miR-
150-5p is in tumor compared to normal or to what degree miR-150-5p was added or 
removed from the cell lines, thus making any comparisons between our data 
impossible. The reason for the disparity between our results could be resolved 
conclusively by performing qRT-PCR for miR-150-5p on FFPE specimens where the 
tumor and adjacent normal cells are separated from each other by laser-capture 
microdissection. miRNAs have successfully been isolated from FFPE  mouse tumors 
by my own lab, and the technique of isolating miRNAs from laser-capture 
microdissected FFPE prostate tissues has been published by the Gann group [196] . 
There are over 4,000 predicted targets of miR-150-5p based on TargetScan 
alone. These targets are a mixture of both oncogenes and tumor suppressors. It is 
possible that each target gene is sensitive to a different level of miR-150-5p. This 
was best demonstrated in the inducible cell lines, which showed leaky expression 
(uninduced) of miR-150-5p (Fig. 3.3C), but had no effect on MYB until the levels 
induced by dox reached the threshold necessary for that particular target (Fig. 3.6C). 
For the inducible ZR-75-1 cell line in particular, leaky expression of miR-150-5p in 
the untreated miR-150 cells did not affect MYB (Fig. 3.6C), but must have been 
enough to affect other targets resulting in growth suppression compared to EV cells 
(Fig. 3.3D). 
In conclusion, my data describes the loss of miR-150-5p expression in breast 
cancers regardless of subtype as well as the effect of restoring miR-150-5p in breast 
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cancer cell lines to physiologically relevant levels observed in well differentiated 
mouse mammary epithelium. My data supports the hypothesis that miR-150-5p 
functions in a subtype specific manner, allowing different genes to be expressed 
when miR-150-5p is lost in breast cancer. Since miR-150 expression can be lost in 
both ER+ and TNBC subtypes, restoration of this miRNA could be a widely effective 
therapy for women where miR-150 is lost. Alternatively, a therapy directed towards 
one or more critical subtype-specific targets could be developed as a therapeutic for 




CONCLUSION AND PERSPECTIVES2 
Bridging Both Sides of the Project Together 
This dissertation describes novel roles of miR-150-5p in both mammary gland 
development and breast cancer. My data indicates that one mechanism responsible 
for the precise timing of secretory activation in the mammary gland is the precipitous 
decrease in miRNAs at late pregnancy and continuing through the start of lactation. 
This post-transcriptional control mechanism provides a way to either have mRNAs 
be extremely high level and poised for translation but not actually be translated until 
the proteins are necessary (as is likely the case with the milk protein genes) or to 
keep the transcript suppressed until necessary (likely the case for the lipid synthesis 
genes (Fig A.1) [9]). Indeed, my investigation of miR-150-5p in the normal mouse 
mammary gland implies that its decreased expression at late pregnancy is essential 
to relieve repression of genes involved in the critical lactation pathway of de novo 
lipid synthesis. While the decrease in this miRNA during normal mammary gland 
development is associated with allowing for function of the ultimate differentiated 
state of MECs, my cancer related data suggests that miR-150-5p plays a tumor 
suppressive role such that loss of miR-150-5p is associated with breast cancer and 
contributes to uncontrolled growth and traits characteristic of increased metastatic 
potential (EMT). How is it possible for a decrease in miR-150-5p to have such 
incongruous results in the same tissue? Below I address these seemingly 
contradictory results. 
                                            
2 Portions of this chapter were accepted for publication in Development 
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To begin to address this issue, it should be kept clear that miR-150-5p is not 
lost during lactation, it is just reduced compared to levels at P14 in normal MECs. 
Compared to breast cancer cell lines, there are still thousands fold higher expression 
levels of miR-150-5p in L2 MECs (Fig. 3.2B). In addition, while miR-150-5p can 
serve as a tumor suppressor as proposed herein and in other cancers described 
earlier [140-143], miR-150-5p has also been described as an oncogene in two other 
carcinomas. These include non-small cell lung cancer, where abnormally high 
expression of miR-150-5p promotes growth though targeting of tumor protein p53 
[197, 198], and gastric cancer, where overexpression of miR-150-5p represses the 
pro-apoptotic gene early growth response protein 2 (EGR2) [199]. Surely, the 
function of miR-150-5p depends on the repertoire of target transcripts available in 
the cell. Indeed this concept is manifested in our finding that it regulates quite 
different targets in ER+ versus TNBC cell lines. 
Since miR-150-5p levels decrease in late pregnancy to allow expression of de 
novo lipid synthesis genes at lactation, I speculated that its levels must return to the 
P14 level of expression in order to regulate secretory activation during a subsequent 
pregnancy. To determine when miR-150-5p levels increase during mammary gland 
development, miR-150-5p ISH was performed on C57BL/6 mouse MGs at 
pregnancy day 5 (P5), pregnancy day 12 (P12), pregnancy day 17 (P17), and 
lactation day 1 (L1) collected previously [200]. The results indicated that miR-150-5p 
expression is low early in pregnancy (P5), increased mid- to late- pregnancy 
(between P12 and P17), and decreased by L1 (Fig. 4.1A). Although it could be a 
whole additional project to fully elucidate the functional role for the rise in miR-150-
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5p at mid-pregnancy, I was curious as to whether the transcripts that it targets when 
it is increasing at mid-pregnancy might be quite different since many of the 
transcripts that it affects at secretory activation involved in lactation are not known to 
be expressed at all during mid-pregnancy. Rather, at mid-pregnancy, the massive 
amount of proliferation of lobular epithelial cells stimulated by ovarian steroid 
hormones estrogen and progesterone must be attenuated to allow for differentiation 
to ensue. To begin to look into this issue I examined a previously published time 
course microarray data (GEO record GSE4222) [201] (Fig. 4.1B). Genes known to 
be critical for lactation, such as miR-150-5p predicted targets Elovl5 and Fads1, are 
expressed at low levels until late pregnancy when they increase [201] consequent to 
the decline of miR-150-5p. Conversely, validated miR-150-5p targets Egr2 [202] and 
Myb [106] decreased at mid-pregnancy just when miR-150-5p increased (Fig. 4.1B). 
Interestingly, these transcripts peak with the proliferation of MECs occurring during 
alveologenesis [203] and both MYB and EGR2 are known to promote proliferation in 
carcinomas [204] including ER+ breast cancer [157] as well as sarcomas [205, 206]. 
Thus, we postulate that the increase in miR-150-5p at mid-pregnancy may serve to 
halt the proliferative expansion of the alveoli to allow for secretory differentiation. 
Thus miR-150-5p possibly serves two entirely different purposes during mammary 
gland development, one when it increases at mid-pregnancy possibly to shut down 
gene products driving proliferation, and another when it decreases just prior to 
secretory activation to relieve expression of genes encoding enzymes involved in 
lipid synthesis as I have demonstrated here, that are essential for lactation. In 




Figure 4.1. miR-150-5p increases at mid-pregnancy concurrently with the 
decrease of proliferation associated genes. (A) A simplified expression pattern of 
mature miR-150-5p in the normal mammary gland based on ISH performed on 
whole mammary glands from C57BL/6 mice at P5, P12, P17 and L2, 400× 
magnification. ISH was performed by Nicole Spoelstra. (B) Time course of 
normalized expression values (log2 transformed) of a selection of validated or 
predicted miR-150-5p target transcripts from whole mammary gland (4 mice per time 































proliferation by targeting Myb, may have more relevance to its apparent tumor 




As reviewed in chapter I, ER+ breast cancer and TNBC are the two of the 
main breast cancer subtypes. Despite the benefit of targeted therapies to ER, ER+ 
some breast cancer patients still develop resistance, resulting in a relapse. As of yet, 
TNBC has no FDA approved targeted therapies. Therefore, new therapies that could 
help treat either or both subtypes would be advantageous for the vast majority of 
breast cancer patients. Because miR-150-5p is lost in breast cancers of both 
subtypes and its restoration slowed proliferation in representative cell line models, 
therapy designed to restore miR-150-5p to breast tumors could possibly be useful 
for both subtypes. 
Much like the mature mimics used to transfect breast cancer cells in Chapter 
III, restoration therapies are being developed that can directly restore mature 
miRNAs to tumors. The existence of two FDA approved oligonucleotide based 
drugs, fomivirsen and mipomersen, show that the pharmaceutical industry is capable 
of mass producing a drug of similar chemistry that can pass FDA approval. Mirna 
Therapeutics has become a leader in the field of miRNA restoration therapy with 
MRX34, a miRNA restoration drug used to restore tumor suppressor miR-34 to 
patients with liver cancer in a trial I study [207]. So far, the only clinical trials 
involving miRNAs are to treat liver cancer. This is because miRNA drugs delivered 
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systemically frequently get trapped in the liver. Several researchers are turning to 
nanotechnology and as a delivery vehicle to transfect miRNA therapies into other 
solid tumors (as reviewed in [208-212]). Other advancements have come in the form 
of chemically modifying the miRNA to aid in transfection and keep it stable [213-
216]. The hope is that by the time the technology has improved in order to safely, 
directly, and more efficiently restore miRNAs to tumors, there will plenty of candidate 
miRNA drugs already tested in the lab. The benefit of miRNA as therapies are that 
they target many genes, but if one or a few targets are critical for the function, new 
targeted therapies or a combination of them may be elucidated by identifying these 
crucial targets. 
In normal development 
 The data presented in Chapter II regarding the role of miRNA in normal 
mammary gland function has clinical significance as well. Knowing that constitutive 
expression of a miRNA can cause a lactation defect in mice suggests that similar 
lactational deficiencies in women, such as low milk yield, could be caused by 
dysregulated miRNAs. 
Low milk yield is a significant health issue because it can discourage women 
from continuing to breastfeed their children. This in turn has negative consequences 
for both the mother and the newborn. For the mother, women with a genetic 
predisposition to breast cancer have a greater risk if they stop breastfeeding within a 
year compared to women who nurse longer [217]. In the baby, depriving them of 
breast milk prevents them from receiving passive immunity via one of the most 
important components in breast milk, the mother’s immunoglobulin A  [218]. For 
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these and other reasons, use of formula instead of milk is not a favorable solution for 
the mother or the infant. Therefore, the better solution is to continue to encourage 
breast feeding and research the causes of lactation deficiencies. 
Future therapies using miRNA antagamirs to suppress overexpressed 
miRNAs would potentially serve as a treatment for lactation deficiencies. Since our 
phenotype observed by forced expression of miR-150 was more dramatic than the 
Fasn knock out [10], we believe that the other targets that I identified in the de novo 
fatty acid synthesis pathway such as ACACA and OLAH are critical.  
As mentioned above for cancer, targets for new therapies can be identified by 
knowing the targets of critical miRNA. There are several known conditions 
associated with low milk yield. One of the major causes of low milk supply, occurring 
in approximately 2.5% of nursing mothers [219], is mastitis. Mastitis is an 
inflammatory condition of one or more ductal branches in the breast. This is usually 
caused by bacterial infection, which leads to an inflammatory response in the 
mammary gland resulting in tissue damage [220]. The resulting damage can also 
affect the ability of mothers to lactate after subsequent pregnancies. Mammals have 
developed an innate immune defense mechanism to keep the mammary gland 
aseptic and prevent mastitis. In mice, this antiseptic agent is hydrogen peroxide, 
produced by L-amino acid oxidase 1 (Lao1) [221]. Interestingly, we found Lao1 to be 
the highest fold increasing predicted target of miR-150-5p between P14 and L2 (fold 
change=21.6, p=0.01) (Fig. 3.2A), and Lao1 was also significantly suppressed by 
constitutive expression of miR-150-5p in L2 MECs (p=0.04). In humans, a related 
molecule encoded by IL-4-induced gene-1 (IL4I1) also produces hydrogen peroxide 
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[222] and is predicted to be targeted by miR-150-5p based on RNA22. While neither 
Lao1 nor IL4I1 are confirmed targets of miR-150-5p, and the role of IL4I1 has yet to 
be studied in the breast, it is possible that aberrant overexpression of miR-150-5p in 
MECs could make mammary glands/breasts more susceptible to developing mastitis 
by preventing translation of these proteins. Study of this mechanism could result in a 
much desired prophylactic therapy to prevent mastitis. 
Other factors known to be associated with low milk yield include obesity [223, 
224] and diabetes [225]. Obesity in particular is known to be involved with impaired 
de novo lipid synthesis in the milk [226]. This suggests a linked mechanism between 
obesity and miR-150-5p. Another connection is that obesity is also a well-known risk 
factor for type 2 diabetes. Knowing what regulates miRNAs as they decrease 
between pregnancy and lactation would further our knowledge towards solving the 
mystery of whether and how metabolic changes that occur with obesity or diabetes 
can impact miRNA expression and therefore lactation. 
New Questions and Future Directions 
Which miRNAs regulate secretory activation in human breasts? 
Since miR-150-5p is relevant in human breast cancer, it may also be relevant 
in breast development as it is in the mouse, particularly at mid-pregnancy where it 
possibly inhibits proliferative expansion. While miR-150-5p can target the 3′ UTR of 
human OLAH and STAT5B, miR-150-5p is not predicted to target the human 3′ UTR 
for FASN or ACACA like it does in mice. Using FASN as an example, Table 1 shows 
that there were several other miRNAs that decreased in the mouse between P14 
and L2 that are predicted to target mouse Fasn. Of which, miR-342-3p has a 
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TargetScan predicted site on the 3′ UTR of human FASN. Interestingly, miR-342-3p 
is not predicted to target the 3′ UTR of human ACACA, STAT5B, or OLAH. 
Therefore, another miRNA or combination of miRNAs, likely serves the purpose of 
regulating FASN and other critical lactation enzymes in humans.  
To determine what miRNAs are relevant in secretory activation for humans 
we propose profiling miRNA expression in miRNAs isolated from milk produced by 
women with normal milk yield compared to women with low milk yield. Isolating the 
miRNAs from milk allows us to noninvasively assess MEC miRNA expression. This 
technique has been demonstrated by Li et. al, who determined that the miRNAs 
isolated from the fat fraction of cow’s milk closely resembles the expression profile of 
miRNAs in the lactating cow’s MECs [227] and by Alsaweed et. al., who showed that 
miRNAs can be isolated from this same fraction in human milk [228]. We expect the 
low-yielders to express higher levels of miRNAs that are either predicted or known 
targets of genes involved in de novo lipid synthesis or other pathways critical to 
lactation. This may or may not include miR-150-5p, but it could include some of the 
other miRNAs listed in Figure 2.1 that we identified in the mouse. 
What regulates miR-150-5p at secretory activation? 
 We were curious about what causes miR-150-5p levels to decline just prior to 
secretory activation. A likely candidate is b-catenin which is known to regulate the 
miR-150 gene through a transcription factor complex with TCF/LEF1 [229]. The 
expression pattern for b-catenin itself does not suggest an involvement in miR-150 
activation [9], but its activity can be assessed from the expression patterns of other 
downstream targets such as cyclin D2 and c-myc [151, 152]. Both cyclin D2 and c-
92 
 
myc share a striking similarity to the expression pattern of miR-150-5p [9]. They 
decrease between P14 and L2, which could imply that b-catenin decreases its 
activity (possibly via less nuclear localization) in line with the decreased expression 
of miR-150-5p. This further supports the notion that b-catenin regulates transcription 
of miR-150 in the mammary gland. Another possibility is a hormonal agent with an 
expression pattern that mirrors that of miR-150. Progesterone would regulate miR-
150 through PR, or placental lactogen, which would utilize PRLR, are potential 
candidates. Both are expressed relatively high systemically in the mouse at late 
pregnancy and both rapidly decrease before lactation [230]. PR is known to regulate 
miRNAs in cancer [231]; however, to date no studies have examined miRNA 
regulated by progesterone/PR in well-differentiated MECs during late pregnancy, 
which are bound to be quite different. While b-catenin, progesterone and placental 
lactogen are all potential candidates responsible for regulating miR-150 at the 
transition from late pregnancy to lactation, definitively proving which of these or 
possibly other agents are responsible, is a major undertaking. 
To determine what regulates miR-150-5p in MECs, we propose culturing P14 
primary MECs with or without the individual putative signaling molecules or in 
combination. This is necessary, because cell lines of well-differentiated MECs that 
are fully competent to lactate and express miR-150 do not exist. By replacing the 
media with a version missing the compound to be tested we could test whether the 
decreases in miR-150-5p occurs. We would expect miR-150 levels to decrease 
when the correct hormone or transcription factor is tested. Conversely, adding the 
agent back in would presumably make miR-150-5p increase again. This of course 
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will all depend on whether P14 levels of miR-150-5p can be maintained in culture. If 
they can’t be maintained in 2D culture, they may be able to remain in a P14 state 
better when grown in 3D culture as was done by Wang and Kaplan [232].  
What is the cause for a loss of miR-150 -5p in breast cancer? 
Lastly, what causes the loss of miR-150-5p in breast cancer? Tumor 
suppressor miRNAs, such as miR-150-5p, can be lost in several ways. 
One mechanism of miRNA loss in cancer is methylation of the CpG islands 
around the miRNA promoter, thereby silencing the gene. The miR-200 family of 
miRNAs are frequently silenced by this method in breast cancer [233]. However, I 
postulate that this type of epigenetic alteration is unlikely to regulate hsa-miR-150 
because there are no CpG islands within 2000 nucleotides up or downstream of the 
gene as determined with EMBOSS Cpgplot [234]. 
Another mechanism of miRNA loss in cancer is through deletions or 
mutations. A good example of a miRNA frequently deleted in breast cancer is the let-
7 family of miRNAs [235]. We examined the sequence encoding human miR-150 for 
genetic alterations by accessing the The Cancer Genome Atlas (TCGA) through 
cBioportal and mutations or major deletions were not apparent in the region of 
human chromosome 19 encoding miR-150 [236, 237]. Microdeletions in this region 
do remain a possibility. 
One additional mechanism of miRNA loss in cancer is incomplete processing 
of immature miRNA. This can be caused by defective processing enzymes like dicer 
or drosha, described in Chapter I. Dicer can be defective or lost in cancer, 
preventing pre-miRNA from being processed into mature miRNA. My mentor’s 
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laboratory has shown dicer to be expressed at significantly lower levels in TNBC 
compared to ER+ breast cancer or adjacent non-tumor epithelium [165], and this is 
likely the reason why TNBC has lower expression of most miRNAs compared to 
ER+ breast cancer [120]. To test this, qRT-PCR can be performed to quantify the 
pre-miRNA and compare it to levels of mature miRNA. Low mature levels compared 
to pre-miRNA levels suggest a bottle neck in miRNA processing specifically with 
dicer. While low dicer offers an explanation for why miR-150-5p is low in TNBC, it 
does not explain the low level of miR-150-5p in ER+ breast cancer.  
Loss of miRNA-150 in breast cancer could be due to a combination of several 
of the abovementioned or unknown factors. Other publications describing the tumor 
suppressive role of miR-150 did not provide information regarding how miR-150-5p 
is lost in breast cancer. 
In summary, while as with most interesting scientific projects, the research 
presented here has resulted in many additional questions, it has brought to light 
several very significant findings. First, is the confirmation of our hypothesis that 
miRNAs provide a level of post-transcriptional control over secretory activation and 
consequent lactation. This finding explains the exquisite fine tuning and dramatic 
changes in gene expression and translation observed in this process so critical to 
the survival of mammals. Secondly, from my data in both the normal mammary 
gland and breast cancer, my findings regarding miR-150-5p exemplify the context 
specific function of miRNA, whereby very different targets can be affected at 
different developmental time points or in different subtypes of cancer. If nothing is 
driving transcription of a particular gene, the effect of a miRNA targeting and 
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repressing that gene will not be evident and is indeed not required. Lastly, as 
discussed above, this research has direct clinical significance, since clinical trials 
utilizing microRNAs as therapeutic agents are underway, and new delivery 
technologies and modifications of miRNA to enhance stability and targeted delivery 
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Clinical Shadowing Experience 
As part of the requirements for the Clinical Translational Science Certificate, I 
participated in clinical shadowing of Dr. Virginia Borges at the University of Colorado 
Hospital Anschutz Outpatient Pavilion. I shadowed Dr. Borges in the mornings when 
she has visits from her patients currently receiving treatment for primary or 
metastatic breast cancer as well as in the afternoons when former patients came in 
for their routine visit. Dr. Borges specializes in young women’s breast cancer, i.e. 
women under 50 years of age with breast cancer. I also attended a few breast tumor 
board meetings. The following is my report of my clinical shadowing experience. 
Breast cancer is more commonly a disease of ageing, affecting many more 
elderly patients than young women. I discovered that treatment of women under 50 
years old comes with several additional challenges.  
Reproductive health was one major concern in the clinic. Some of the 
youngest patients I met were my own age or younger, with young children or plans 
on having their own family. Some of the topics discussed between Dr. Borges and 
her patients were the option of freezing eggs or embryos, since one side effect of 
chemotherapy is sterility. In addition, Tamoxifen is one of the drugs pregnant women 
cannot take, so it is usually postponed if the patient is currently pregnant. Meanwhile 
the tumor can still b treated using other methods that don’t affect the baby. The side 
effects of tamoxifen on pregnancy are so severe that treatment would have to stop if 
a patient got pregnant during her regiment. This would risk the health of the baby, 
and delay this beneficial cancer treatment for 9 months. For this reason, Dr. Borges 
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occasionally had to discuss birth control with her patients. Something I took from this 
was to keep in mind the effect new therapies would have on reproductive health, 
which is a quality of life issue for the younger patients. 
Another major concern with young patients is reconstructive surgery after 
mastectomy. Almost all young women elect to have bilateral mastectomies after their 
initial diagnosis, even though there is little scientific evidence that this procedure 
decreases the risk of a relapse. After mastectomy, the patients almost always get 
reconstructive surgery. I learned a few things about reconstructive surgery during my 
shadowing experience that I was not aware of beforehand. For example, implants go 
under the pectoral muscles. This surprised me because the mammary glands sit on 
top of the muscles beneath the breast. To facilitate a space for these implants, 
spacers are used to stretch out an opening under the pectoral muscles. Several 
patients were using spacers during their visits in anticipation for reconstructive 
surgery following their chemotherapy. 
By shadowing Dr. Borges, I was able to witness firsthand the joy of new 
cancer treatments being successful in patients as part of clinical trials. The vaccine 
against MUC1 was incredibly interesting to me. It utilizes the body’s own immune 
system to directly target MUC1, which is expressed by the tumor cells. The patients 
showed improvements, they came into the clinic happy without any side-effects, and 
it only required a few shots each visit in different locations. 
One of the main take home messages for me was that treatments have wide 
ranging side-effects, and we don’t always think about those along with quality of life 
issues when we in the laboratory are primarily focused on the effects the drugs have 
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on the cancer. We also need to think of ways to treat cancer that have the least 
amount of side effects, whether that would be a new approach like a cancer vaccine 
or a combination of drugs that have synergistic effects and thus can be used at 
lower potency to possibly result in fewer side-effects. 
I also thought about a rather simple solution to a problem faced in the clinic. 
For patients undergoing chemo for non-metastatic breast cancer, hair loss can be a 
major concern, especially for women, and even more so for young women. There is 
always the risk that hair will not grow back as full after chemotherapy. To remedy 
this, cold caps are used. These are essentially frozen hats that cover the scalp to 
suppress blood flow, and therefore drug delivery, to the scalp during chemotherapy. 
Several caps are purchased by the patient, frozen on dry ice, worn, and switched out 
during administration of chemotherapy. A new version of a cold cap even has the 
coolant circulate into the cap, so you only need one cap without rotating with several 
at a time. As for the traditional cold caps, they are not cheap, and once the patient 
has completed chemotherapy, they hopefully won’t need to use them again for a 
long time. To my understanding they are completely reusable, so I proposed these 
should be serializable and then available to sell or donate to a place like 
GoodHealthwill that sells other reusable medical devices such as wheelchairs and 
crutches. This would offer a low cost source for this beneficial medical equipment. 
On a more personal note, as I shadowed in the clinic, and wrote about my 
clinical experience, I couldn’t help but recall the memories of my own mother getting 
treated for her breast cancer. Just like many of Dr. Borges’ patients, my mom was 
under 50 with 3 young children when she was first diagnosed in 1989. All I 
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remember of that time was spending a few nights over at a relative’s or friend’s 
house probably when my mom was having surgery and radiation treatments. My 
mom didn’t want to scare us, and I doubt any of us would have fully understood what 
it meant that our mom had cancer. 
Breast cancer was still taboo to talk about at that time, and there wasn’t the 
same support group for breast cancer survivors as there is now. Neighbors informed 
of my mom’s diagnosis were less than supportive. I think my mom told me some 
were scared as if breast cancer was contagious. When October, aka breast cancer 
awareness month, rolled around, there was no 5K race or pink ribbons. Current 
patient try to avoid these celebrations since they are well aware that they have 
breast cancer, and do not appreciate the reminders. Even though the events may be 
avoided by patients currently receiving treatment, the current public awareness 
campaign has been a world of difference to those survivors happy to be alive and 
hopeful for a cure before their cancer metastasizes.  
My mom didn’t always have the best doctors looking out for her. She switched 
doctors at least once after being told by an uncompassionate physician that she 
would frankly die from breast cancer. One of the prerequisites for anyone 
considering a job in the medical field must be compassion. I can’t imagine Dr. 
Borges ever saying that to a patient, no matter how dire the patient seems. On the 
rare occasion I witnessed Dr. Borges have to give bad news, she always looked at 
the good side and was there to console the patient. For example, one patient was on 
a trial for her metastatic cancer. The cancer was growing, so she had to be removed 
from the study. On the positive side, there were other treatments available that still 
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had potential. The patients were always given all the time they needed to release 
their sadness with Dr. Borges before she moved on to the next patient, and almost 
all of Dr. Borges visits ended with a hug. 
Another example of when I don’t think she was in the best care was in the 
summer of 2003 when she first had symptoms of the lung metastasis that ultimately 
took her life. Now that I am aware that breast cancer can metastasize many years 
after it was initially diagnosed, and how lungs are a common site, I am baffled at 
how long my mom went on with symptoms before being properly diagnosed. She 
was given several prescription heartburn medications at one point to see which one 
would work, but it wasn’t heartburn. I wouldn’t be surprised if the doctor I’m referring 
to in both stories was the same person. Luckily, my mom did find a great doctor at 
the end. He was compassionate, hopeful to try new treatments, and even attended 
my mom’s wake. While giving the patients hope is very important, I think patients 
should also be aware that the risk for metastasis is there and what symptoms to be 
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Figure A.1. Expression patterns of genes relevant to lactation. (A) High 
expressing milk protein genes showing an increase in pregnancy (4- to 20-fold) and 
a 2-fold increase on L2. This is a Slide Write plot of the mean normalized intensities 
at each time point with error bars showing the SEM. (B) Genes for the enzymes of 
lipid synthesis. All genes from the lipid synthesis group are shown normalized to the 
median value for each gene with the standard error for each data point. The average 
profile, generated in GeneSpring, is shown in the inset. From Rudolph, M.C., et al., 
Functional development of the mammary gland: use of expression profiling and 
trajectory clustering to reveal changes in gene expression during pregnancy, 




Figure A.2. Key pathways involved in secretory activation are altered in 
pregnancy versus lactation. Pathways represented by mRNAs changed in P14 
versus L2 as measured by GeneChip Mouse Gene 1.0 ST array in CD1 MECs 
analyzed by IPA. Pathways are sorted in order of decreasing statistical significance 
(-log of p-value), represented by black bars with values indicated on the top axis. 
Grey line represents the percent of genes in each pathway that were altered with 
values indicated on the bottom axis. Only the top 13 significantly altered canonical 






Figure A.3. Constitutive expression of miR-150 in mammary epithelium 
throughout lactation did not affect the normal expression pattern of miR-146b-
5p, which increases at L2 compared to P14. TaqMan qRT-PCR was used to 
quantify mature miR-146b-5p expression in RNA isolated from L2 and P14 MECs 
from the indicated genotype normalized to RNAU6. Error bars represent standard 





Figure A.4. Constitutive miR-150 did not suppress lipid droplet formation. IHC 
for adipophilin in mammary glands at P18 (3 mice per indicated genotype) and 








Figure A.5. Constitutive miR-150 does not affect JAK2 activation or milk 
protein expression downstream of STAT5. Immunoblot analysis of isolated L2 
MECs. Blots were probed with primary antibodies, washed and incubated with 
appropriate peroxidase-conjugated secondary antibodies, and developed using 
enhanced chemiluminescence. The primary antibodies used were anti-CK18 (Santa 
Cruz 28264), anti-pJAK2 (Tyr1007/1008) (Cell Signaling, C80C3), anti-JAK2 (Cell 
Signaling, D2E12), anti-β-casein (Santa Cruz, 17969), and anti-α-tubulin loading 
control (Sigma, T5168). Film was scanned using a CanoScan 8600F (Canon, Tokyo, 
Japan) and densitometry of bands were quantified with ImageJ (National Institutes of 
Health). Immunoblot for WAP was done by Odyssey infrared imager described in 














Table A.1. Significantly decreased miRNAs predicted to target milk protein 
genes that increased between P14 and L2. 
 
Significant downregulated miRNAs are listed on the left, sorted from large to small 
fold change indicated in parenthesis. Milk protein genes that were TargetScan 
predicted targets of each miRNA are listed on the right. Numbers in parenthesis 
indicate fold increase of gene expression at L2 compared to P14 in the Affymetrix 
Mouse Gene 1.0 ST array. miRNAs that are part of the miR-17/92 cluster are in bold. 
miRNA (-FC) Predicted Gene Targets (+FC)
miR-150-5p (7.6) Egf (6.7), Btn1a1 (4.3), Mfge8 (4.0)
miR-342-3p (4.4) Ltf (9.4), Lpo (8.2), Xdh (6.3)
miR-20b-5p (3.8) Ltf (9.4)
miR-146a-5p (2.9) Egf (6.7)
miR-361-5p (2.8) Cel (12.9)
miR-342-5p (2.7) Muc1 (8.5), Egf (6.7), Mfge8 (4.0)
miR-140-3p (2.6) Egf (6.7), Xdh (6.3)
miR-191-5p (2.6) Xdh (6.3)
miR-425-5p (2.5) Ltf (9.4), Egf (6.7), Btn1a1 (4.3)
miR-155-5p (2.5) Egf (6.7), Xdh (6.3), Btn1a1 (4.3)
miR-18a-5p (2.5) Btn1a1 (4.3)
miR-106a-5p (2.5) Ltf (9.4)
miR-17-3p (2.4) Ltf (9.4), Egf (6.7)
miR-17-5p (2.3) Ltf (9.4)
miR-150-3p (2.1) Btn1a1 (4.3), Mfge8 (4.0), Csn1s2b (1.8)
miR-29a-3p (2.1) Wfdc3 (13.1)
miR-185-5p (2.1) Xdh (6.3)
miR-532-5p (2.0) Csn2 (1.3)
